<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="generator" content=
"HTML Tidy for HTML5 for Mac OS X version 5.4.0" />
<title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">
<p style="margin: 0"></p>
<!-- Field: Rule-Page -->
<div align="left" style="margin-top: 0; margin-bottom: 0">
<div style=
"font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">
&nbsp;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0">&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>WASHINGTON, D.C. 20549</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>FORM 10-Q</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
☒ Quarterly Report Pursuant to Section13 or 15(d) of the Securities
Exchange Act of 1934</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
for the Quarterly Period Ended March 31,2018</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
-OR-</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
☐ Transition Report Pursuant to Section13 or 15(d) of the
Securities Exchange Act of 1934</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
for the transaction period from _________to________</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Commission File Number<b>: 000-54716</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b><u>NeuroOne Medical Technologies Corporation</u></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(Exact name of Registrant as specifiedin its charter)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style=
"width: 49%; border-bottom: black 1.5pt solid; text-align: center">
<font style="font-size: 10pt"><b>Delaware</b></font></td>
<td style="width: 2%; padding-bottom: 1.5pt; text-align: center">
&nbsp;</td>
<td style=
"width: 49%; border-bottom: black 1.5pt solid; text-align: center">
<font style="font-size: 10pt"><b>27-0863354</b></font></td>
</tr>
<tr>
<td style="vertical-align: bottom; text-align: center"><font style=
"font-size: 10pt">(State or Other Jurisdiction of</font><br />
<font style="font-size: 10pt">Incorporation or
Organization)</font></td>
<td style="vertical-align: bottom; text-align: center">&nbsp;</td>
<td style="vertical-align: top; text-align: center"><font style=
"font-size: 10pt">(I.R.S. Employer</font><br />
<font style="font-size: 10pt">Identification Number)</font></td>
</tr>
<tr>
<td style="text-align: center">&nbsp;</td>
<td style="text-align: center">&nbsp;</td>
<td style="text-align: center">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; text-align: center">
<font style="font-size: 10pt"><b>10006 Liatris Lane, Eden Prairie,
MN</b></font></td>
<td style="padding-bottom: 1.5pt; text-align: center">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; text-align: center">
<font style="font-size: 10pt"><b>55347</b></font></td>
</tr>
<tr style="vertical-align: bottom">
<td style="text-align: center"><font style=
"font-size: 10pt">(Address of Principal Executive
Offices)</font></td>
<td style="text-align: center">&nbsp;</td>
<td style="text-align: center"><font style="font-size: 10pt">(Zip
Code)</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Registrant’s Telephone Number, IncludingArea Code:
<b>952-237-7412</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Not Applicable</b><br />
(Former name or former address, if changed since last report)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Indicate by check mark whether the issuer(1) filed all reports
required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding12 months (or for such
shorter period that the registrant was required to file such
reports), and (2) has been subject to suchfiling requirements for
the past 90 days. Yes&nbsp;☒&nbsp;No&nbsp;☐</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Indicate by check mark whether the registranthas submitted
electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submittedand posted pursuant
to Rule 405 of Regulation S-T (section 232.405 of this chapter)
during the preceding 12 months (or for suchshorter period that the
registrant was required to submit and post such files).
Yes&nbsp;☒&nbsp;No&nbsp;☐</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Indicate by check mark whether the registrantis a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company, or an emerging growthcompany. See the
definitions of “large accelerated filer”, “accelerated filer”, 
“smaller reportingcompany”, and “emerging growth company” in Rule
12b-2 of the Exchange Act:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td nowrap="nowrap" style="width: 35%"><font style=
"font-size: 10pt">Large accelerated filer</font></td>
<td style="width: 12%"><font style="font-size: 10pt">☐</font></td>
<td nowrap="nowrap" style="width: 48%"><font style=
"font-size: 10pt">Non-accelerated filer</font></td>
<td style="width: 5%"><font style="font-size: 10pt">☐</font></td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap"><font style="font-size: 10pt">Accelerated
filer</font></td>
<td><font style="font-size: 10pt">☐</font></td>
<td nowrap="nowrap"><font style="font-size: 10pt">Smaller reporting
company</font></td>
<td><font style="font-size: 10pt">☒</font></td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td>&nbsp;</td>
<td nowrap="nowrap"><font style="font-size: 10pt">Emerging growth
company</font></td>
<td><font style="font-size: 10pt">☐</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
If an emerging growth company, indicateby check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financialaccounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Indicate by check mark whether the registrantis a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes&nbsp;☐
No&nbsp;☒</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The number of outstanding shares of theregistrant’s common stock as
of May 14, 2018 was 8,014,994.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<!-- Field: Rule-Page -->
<div align="left" style="margin-top: 3pt; margin-bottom: 0">
<div style=
"font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">
&nbsp;</div>
</div>
<!-- Field: /Rule-Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<p style="margin: 0pt">&nbsp;</p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>NEUROONE MEDICAL TECHNOLOGIES CORPORATION</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>FORM 10-Q</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>INDEX</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="width: 7%">&nbsp;</td>
<td style="width: 86%; padding-left: 10pt; text-indent: -10pt">
&nbsp;</td>
<td style=
"width: 7%; border-bottom: black 1.5pt solid; text-align: center">
<font style="font-size: 10pt"><b>Page</b></font></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td style="padding-left: 10pt; text-align: center"><font style=
"font-size: 10pt">PART 1 – FINANCIAL INFORMATION</font></td>
<td style="text-align: center">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Item 1.</font></td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Financial Statements</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">1</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Condensed Consolidated Balance Sheets as of March
31, 2018 (unaudited) and December 31, 2017</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">1</font></td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Condensed Consolidated Statements of Operations
for the three months ended March 31, 2018 and 2017
(unaudited)</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">2</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Condensed Consolidated Statements of Cash Flows
for the three months ended March 31, 2018 and 2017
(unaudited)</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">3</font></td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Notes to Condensed Consolidated Financial
Statements (unaudited)</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">4</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt">Item 2.</font></td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Management’s Discussion and Analysis of Financial
Condition and Results of Operations</font></td>
<td style="text-align: center">21</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Item 3.</font></td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Quantitative and Qualitative Disclosures About
Market Risk</font></td>
<td style="text-align: center">30</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt">Item 4.</font></td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Controls and Procedures</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">30</font></td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
<td style="text-align: center">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&nbsp;</td>
<td style=
"padding-left: 10pt; text-align: center; text-indent: -10pt">
<font style="font-size: 10pt">PART II – OTHER
INFORMATION</font></td>
<td style="text-align: center">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
<td style="text-align: center">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt">Item 1.</font></td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Legal Proceedings</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">31</font></td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Item 1A.</font></td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Risk Factors</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">32</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt">Item 2.</font></td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Unregistered Sales of Equity Securities and Use
of Proceeds</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">32</font></td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Item 3.</font></td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Defaults Upon Senior Securities</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">32</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt">Item 4.</font></td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Mine Safety Disclosures</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">32</font></td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td><font style="font-size: 10pt">Item 5.</font></td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Other Information</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">32</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td><font style="font-size: 10pt">Item 6.</font></td>
<td style="padding-left: 10pt; text-indent: -10pt"><font style=
"font-size: 10pt">Exhibits</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">32</font></td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&nbsp;</td>
<td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
<td style="text-align: center">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td colspan="2"><font style=
"font-size: 10pt">SIGNATURES</font></td>
<td style="text-align: center"><font style=
"font-size: 10pt">33</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</p>
<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt">
<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>PART I – FINANCIAL INFORMATION</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Item 1. Financial Statements</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>NeuroOne Medical Technologies Corporation</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Condensed Consolidated Balance Sheets</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March&nbsp;31,</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&nbsp;31,</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style=
"border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style=
"border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2017</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: center; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Assets</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: right; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: right; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
assets:</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: right; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: right; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 76%; padding-left: 10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="width: 9%; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">25,198</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="width: 9%; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">26,467</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">7,146</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">7,146</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
current assets</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">32,344</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">33,613</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">211,420</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">216,372</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
assets</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">243,764</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">249,985</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liabilities
and Stockholders’ Deficit</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
liabilities:</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">1,522,874</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">1,021,617</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
promissory notes and unsecured loan, net of discount</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">369,124</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">253,000</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
promissory notes, net and accrued interest</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">2,505,089</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">2,168,340</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Premium
conversion derivatives</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">607,173</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">462,174</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
current liabilities</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">5,004,260</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">3,905,131</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
liability</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">1,634,059</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">1,381,465</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
liabilities</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">6,638,319</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">5,286,596</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
and contingencies (Note 4)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders’
 deficit:</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style=
"padding-left: 20pt; text-indent: -10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
stock, $0.001 par value; 10,000,000 shares authorized as of March
31, 2018 and December 31, 2017; no shares issued or outstanding as
of March 31, 2018 and December 31, 2017.</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">—
</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">—
</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style=
"padding-left: 20pt; text-indent: -10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
stock, $0.001 par value; 100,000,000 shares authorized as of March
31, 2018 and December 31, 2017; and 7,864,994 shares issued and
outstanding as of March 31, 2018 and December 31, 2017.</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">7,865</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">7,865</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
paid–in capital</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">279,150</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">280,320</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
deficit</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,681,570</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,324,796</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
stockholders’ deficit</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,394,555</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,036,611</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
liabilities and stockholders’ deficit</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">243,764</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">249,985</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
See accompanying notes to condensed consolidated
financialstatements</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>NeuroOne Medical Technologies Corporation</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Condensed Consolidated Statements ofOperations</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>(unaudited)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="6" style=
"border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the three months ended</b></font><br />
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
31,</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style=
"border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style=
"border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2017</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: right; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: right; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
expenses:</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: right; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: right; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 76%; padding-left: 10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="width: 9%; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">992,435</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="width: 9%; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">444,016</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">105,045</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">72,041</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
operating expenses</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">1,097,480</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">516,057</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
from operations</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,097,480</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(516,057</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(193,034</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(213,550</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
change in fair value for the warrant liability and premium
conversion derivatives</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">119,960</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">32</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
on short-term notes extinguishment</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(186,220</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">—
</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,356,774</font></td>
<td style="line-height: 107%; padding-bottom: 4pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(729,575</font></td>
<td style="line-height: 107%; padding-bottom: 4pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss per share:</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.17</font></td>
<td style="line-height: 107%; padding-bottom: 4pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.14</font></td>
<td style="line-height: 107%; padding-bottom: 4pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of shares used in per share calculations:</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="padding-left: 10pt; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">7,864,994</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">5,216,565</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
See accompanying notes to condensed consolidated
financialstatements</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<!-- Field: Page; Sequence: 4; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>NeuroOne Medical Technologies Corporation</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>Condensed Consolidated Statements ofCash Flows</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>(unaudited)</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="text-align: center">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
For the three months ended<br />
March 31,</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
2018</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
2017</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold">Operating activities</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">
Net loss</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">(1,356,774</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">(729,575</td>
<td style="width: 1%; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 10pt">
Adjustments to reconcile net loss to net cash used in operating
activities:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-indent: -10pt; padding-left: 20pt">
Amortization</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">4,952</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,007</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 20pt">
Stock-based services expense</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">254,437</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash
interest on short-term and convertible promissory notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">54,116</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">17,887</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 20pt">Non-cash
discount amortization on convertible promissory notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">138,918</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">178,541</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 20pt">Note
issuance costs attributed to warrant liability</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">15,803</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 20pt">
Revaluation of premium conversion derivatives</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">4,032</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">183</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 20pt">
Revaluation of warrant liability</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(123,992</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(215</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 20pt">Loss on
short-term notes extinguishment</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">186,220</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 20pt">Change
in assets and liabilities:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 30pt">Prepaid
expenses</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">53,823</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">
Accrued expenses</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
246,822</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
107,627</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">
Net cash used in operating activities</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
(591,269</td>
<td style="padding-bottom: 1.5pt; text-align: left">)</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
(350,919</td>
<td style="padding-bottom: 1.5pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">
Financing activities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds
from issuance of convertible promissory notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">236,136</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">192,427</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 10pt">Proceeds
from issuance of warrants associated with short-term and
convertible promissory notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">238,864</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">182,693</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 10pt">
(Repayment) proceeds from short term unsecured loan</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">115,000</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(50,000</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 10pt">Issuance
costs related to convertible promissory notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(5,130</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">
Issuance costs related to warrants</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">—
</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
(4,870</td>
<td style="padding-bottom: 1.5pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">
Net cash provided by financing activities</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
590,000</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
315,120</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; text-indent: -10pt; padding-left: 10pt">Net
decrease in cash</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(1,269</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(35,799</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">
Cash at beginning of period</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
26,467</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
522,217</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Cash
at end of period</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
25,198</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
486,418</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10pt">
Supplemental non-cash financing and investing transactions:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">
Bifurcation of premium conversion derivative related to convertible
promissory notes</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
91,298</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
72,732</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">
Accrued issuance costs attributed to convertible promissory
notes</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">—
</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
16,645</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">
Accrued issuance costs attributed to warrant liability</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">—
</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
15,803</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
See accompanying notes to condensed consolidated
financialstatements</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</p>
<!-- Field: Page; Sequence: 5; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE1 – Organization and Basis of Presentation</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
NeuroOne Medical Technologies Corporation(the “Company”), a
Delaware Corporation, was originally incorporated as Original
Source Entertainment, Inc. under thelaws of the State of Nevada on
August 20, 2009. Prior to the closing of the Acquisition (as
defined below), the Company completeda series of steps contemplated
by a Plan of Conversion pursuant to which the Company, among other
things, changed its name to NeuroOneMedical Technologies
Corporation, increased its authorized number of shares of common
stock from 45,000,000 to 100,000,000, increasedits authorized
number of shares of preferred stock from 5,000,000 to 10,000,000
and reincorporated in Delaware. On July 20, 2017,the Company,
through a wholly owned acquisition subsidiary, acquired 100% of the
outstanding capital stock of NeuroOne, Inc. (“NeuroOne”)in a
reverse triangular merger and reorganization pursuant to Section
368(a) of the Internal Revenue Code (the “Acquisition”).The
Acquisition was accounted for as a capital transaction, or reverse
recapitalization. NeuroOne was the accounting acquirer inthis
transaction. As such, the historical financial statements of
NeuroOne reflect operations of the Company for all periods
presentedprior to the date of the Acquisition. The accompanying
condensed consolidated financial statements subsequent to the
Acquisitioninclude those of the Company, as well as those of its
wholly owned subsidiary NeuroOne.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Subsequent to the Acquisition, the Company’soperating activities
became the same as those of NeuroOne, an early-stage medical
technology company developing comprehensiveneuromodulation cEEG and
sEEG monitoring, ablation, and brain stimulation solutions to
diagnose and treat patients with epilepsy,Parkinson’s disease,
essential tremors, and other brain related disorders.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
To date, the Company has recorded no productsales and has a limited
expense history. The Company is a development stage company and its
activities to date have included raisingcapital to fund the
development of its proprietary technology and seek regulatory
clearances required to initiate commercial activities.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company is based in Eden Prairie,Minnesota.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Acquisition of NeuroOne, Inc.</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Acquisition was consummated on July20, 2017 (the “Closing”)
and, pursuant to the terms of the merger agreement, (i) all
outstanding shares of commonstock of NeuroOne, par value $0.0001
per share (the “NeuroOne Shares”), were exchanged for shares of the
Company’scommon stock, par value $0.001 per share (the “Company
Shares”), based on the exchange ratio of 17.0103706 CompanyShares
for every one NeuroOne Share (the “Exchange Ratio”), resulting in
the Company issuing, on July 20, 2017, anaggregate of 6,291,994
Company Shares for all of the then-outstanding NeuroOne Shares,
(ii) all outstanding options of NeuroOnewere replaced with options
to purchase Company Shares based on the Exchange Ratio, with
corresponding adjustments to their respectiveexercise prices,
pursuant to which the Company reserved 992,265 Company Shares for
issuance upon the exercise of options, (iii)all warrants of
NeuroOne were replaced with warrants to purchase Company Shares and
(iv) the Company assumed the outstanding convertiblepromissory
notes of NeuroOne. NeuroOne options had been issued pursuant to the
NeuroOne 2016 Equity Incentive Plan. Pursuant tothe merger
agreement, the Company assumed the NeuroOne 2016 Equity Incentive
Plan upon the Closing.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Pursuant to the Acquisition, the Companyacquired 100% of NeuroOne
Shares in exchange for the issuance of Company Shares and NeuroOne
became the Company’s wholly-ownedsubsidiary. Also at the Closing,
Mr. Samad (the majority owner of the Company prior to the
Acquisition) tendered for cancellation3,500,000 Company Shares held
by him as part of the conditions to Closing.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
All issued and outstanding common stockshare amounts, options for
common stock and per share amounts contained in the consolidated
financial statements were retroactivelyadjusted to reflect the
Exchange Ratio for all periods presented.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 6; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b><i>Basis of presentation</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The accompanying condensedconsolidated financial statements have
been prepared by the Company, without audit, pursuant to the rules
and regulations ofthe Securities and Exchange Commission (the “SEC”
). Certain information and footnote disclosures normallyincluded in
financial statements prepared in accordance with U.S. generally
accepted accounting principles (GAAP) have beencondensed or omitted
pursuant to such rules and regulations. The condensed consolidated
financial statements may not includeall disclosures required by
U.S. GAAP; however, the Company believes that the disclosures are
adequate to make theinformation presented not misleading. These
unaudited condensed consolidated financial statements should be
read inconjunction with the audited financial statements and the
notes thereto for the fiscal year ended December 31, 2017
includedin the Annual Report on Form 10-K for the year ended
December 31, 2017. The condensed balance sheet at December 31, 2017
wasderived from the audited financial statements of the
Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In the opinion of management, all adjustments,consisting of only
normal recurring adjustments that are necessary to present fairly
the financial position, results of operations,and cash flows for
the interim periods, have been made. The results of operations for
the interim periods are not necessarilyindicative of the operating
results for the full fiscal year or any future periods.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Certain prior period balances have been reclassified to conformto
the current period presentation. Specifically, the Company
reclassified all fair market valuation adjustments related to
thewarrant liability and to the premium conversion derivative from
interest expense to a separate line item on the condensed
consolidatedstatements of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<!-- Field: Page; Sequence: 7; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE2 – Going Concern</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The accompanying condensed consolidatedfinancial statements have
been prepared on the basis that the Company will continue as a
going concern. The Company has incurredlosses since inception and
had an accumulated deficit of $6,681,570 as of March 31, 2018. The
Company does not have adequate liquidityto fund its operations
throughout fiscal 2018 without raising additional funds. These
factors raise substantial doubt about itsability to continue as a
going concern. The condensed consolidated financial statements do
not include any adjustments that mightresult from the outcome of
this condition. Management intends to continue to seek additional
financing to fund operations. If theCompany is not able to raise
additional working capital, it will have a material adverse effect
on the operations of the Companyand the development of its
technology.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Through March 31, 2018, the Company hascompleted a $115,000
unsecured loan financing, a $253,000 short-term promissory note
financing (which notes were amended and restatedto become
convertible promissory notes as described below), a $1,625,120
convertible promissory note financing of a planned $2.5million
subscription and a second $1,140,000 convertible promissory note
financing of a planned $2 million subscription. See Note13 –
Subsequent Events for financings that have closed after March 31,
2018. The Company does not have adequate liquidityto fund its
operations throughout fiscal 2018 without raising additional funds.
Management intends to continue to seek additionaldebt and/or equity
financing to fund operations. However, if the Company is unable to
raise additional funds, or the Company’santicipated operating
results are not achieved, management believes planned expenditures
may need to be reduced in order to extendthe time period that
existing resources can fund the Company’s operations. If management
is unable to obtain the necessarycapital, it may have to cease
operations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE3 – Summary of Significant Accounting Policies</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Management’s Use ofEstimates</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The preparation of condensed consolidatedfinancial statements in
conformity with accounting principles generally accepted in the
United States of America requires managementto make estimates and
assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assetsand liabilities at
the date of the condensed consolidated financial statements and the
reported amounts of expenses during thereporting period. Actual
results could differ from those estimates.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Concentration of Credit Risk</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Financial instruments that potentiallysubject the Company to a
concentration of credit risk consist of cash. The Company’s cash is
held by one financial institutionin the United States. Amounts on
deposit may at times exceed federally insured limits. Management
believes that the financialinstitution is financially sound, and
accordingly, minimal credit risk exists with respect to the
financial institution. As ofMarch 31, 2018, the Company did not
have any deposits in excess of federally insured amounts.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Fair Value of Financial Instruments</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company’s accounting for fairvalue measurements of assets and
liabilities that are recognized or disclosed at fair value in the
condensed consolidated financialstatements on a recurring or
nonrecurring basis adheres to the Financial Accounting Standards
Board (FASB) fair value hierarchythat prioritizes the inputs to
valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjustedquoted prices in active
markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to measurementsinvolving significant
unobservable inputs (Level 3 measurements). The three levels of the
fair value hierarchy are as follows:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -0.5in">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 48px"><font style="font-size: 10pt">●</font></td>
<td style="text-align: justify"><font style="font-size: 10pt">Level
1 Inputs: Unadjusted quoted prices in active markets for identical
assets or liabilities accessible to the Company at the measurement
date.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -0.5in">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 48px"><font style="font-size: 10pt">●</font></td>
<td style="text-align: justify"><font style="font-size: 10pt">Level
2 Inputs: Other than quoted prices included in Level 1 inputs that
are observable for the asset or liability, either directly or
indirectly, for substantially the full term of the asset or
liability.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -0.5in">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 48px"><font style="font-size: 10pt">●</font></td>
<td style="text-align: justify"><font style="font-size: 10pt">Level
3 Inputs: Unobservable inputs for the asset or liability used to
measure fair value to the extent that observable inputs are not
available, thereby allowing for situations in which there is
little, if any, market activity for the asset or liability at
measurement date.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 8; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
As of March 31, 2018 and December 31,2017, the fair values of cash,
other assets, accrued expenses and the unsecured loan approximated
their carrying values becauseof the short-term nature of these
assets or liabilities. The estimated fair value of the short-term
and convertible promissorynotes of the Company was based on
amortized cost which was deemed to approximate fair value. The fair
value of the warrant liabilityand the premium conversion
derivatives associated with the short-term and convertible
promissory notes of the Company were basedon cash flow models
discounted at current implied market rates evidenced in recent
arms-length transactions representing expectedreturns by market
participants for similar instruments and are based on Level&nbsp;3
inputs. There were no transfers between fairvalue hierarchy levels
during the three months ended March 31, 2018 and 2017.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;&nbsp;&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
The fair value of financial instruments measured on a
recurringbasis is as follows:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="14" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
As of March 31,&nbsp;2018</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">
Description</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
Total</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
Level&nbsp;1</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
Level&nbsp;2</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
Level&nbsp;3</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td>Liabilities:</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%; text-align: left">Warrant liability</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">1,634,059</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">—</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">—</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">1,634,059</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1.5pt">Premium
conversion derivatives</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
607,173</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">—
</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">—
</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
607,173</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total
liabilities at fair value</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
2,241,232</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">—
</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">—
</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
2,241,232</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="14" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
As of December&nbsp;31,&nbsp;2017</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">
Description</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
Total</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
Level&nbsp;1</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
Level&nbsp;2</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
Level&nbsp;3</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td>Liabilities:</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%; text-align: left">Warrant liability</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">1,381,465</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">—</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">—</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">1,381,465</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1.5pt">Premium
conversion derivatives</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
462,174</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">—
</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">—
</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
462,174</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total
liabilities at fair value</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
1,843,639</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">—
</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">—
</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
1,843,639</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The following table provides a roll-forwardof the warrant liability
and premium debt conversion derivatives measured at fair value on a
recurring basis using unobservablelevel&nbsp;3 inputs for the three
month periods ended March 31, 2018 and 2017:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
2018</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
2017</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold">Warrant liability</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: right">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%">Balance as of beginning of period</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">1,381,465</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">345,960</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Value assigned to warrants in
connection with convertible promissory and short-term notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">376,586</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">182,693</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">Change in fair
value of warrant liability</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
(123,992</td>
<td style="padding-bottom: 1.5pt; text-align: left">)</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
(215</td>
<td style="padding-bottom: 1.5pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 4pt; padding-left: 10pt">Balance as of
end of period</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
1,634,059</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
528,438</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
2018</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
2017</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold">Premium debt conversion
derivatives</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: center">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2" style="text-align: center">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%">Balance as of beginning of period</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">462,174</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">137,650</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Value assigned to the underlying
derivatives in connection with convertible promissory and
short-term notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">140,967</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">72,732</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 1.5pt">Change in fair
value of premium debt conversion derivatives</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
4,032</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
183</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 4pt; padding-left: 10pt">Balance as of
end of period</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
607,173</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
210,565</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 9; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Intellectual Property</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company has entered intotwo licensing agreements with major
research institutions, which allows for access to certain patented
technology and know-how.Payments under those agreements are
capitalized and amortized to general and administrative expense
over the expected useful lifeof the acquired technology.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Impairment of Long-Lived Assets</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company evaluates its long-lived assets,which consists entirely
of licensed intellectual property for impairment whenever events or
changes in circumstances indicate thatthe carrying value of these
assets may not be recoverable. The Company assesses the
recoverability of long-lived assets by determiningwhether or not
the carrying value of such assets will be recovered through
undiscounted expected future cash flows. If the assetis considered
to be impaired, the amount of any impairment is measured as the
difference between the carrying value and the fairvalue of the
impaired asset. Through March 31, 2018, the Company has not
impaired any long-lived assets.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Debt Issuance Costs</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Debt issuance costs are recorded as areduction of the convertible
promissory notes and short-term notes when applicable. Amortization
of debt issuance costs is calculatedusing the straight-line method
over the term of the short term notes and convertible promissory
notes, which approximates theeffective interest method, and is
recorded in interest expense in the accompanying consolidated
statements of operations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;&nbsp;<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Research and Development Costs</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Research and development costs are chargedto expense as incurred.
Research and development expenses may comprise of costs incurred in
performing research and developmentactivities, including clinical
trial costs, manufacturing costs for both clinical and pre-clinical
materials as well as othercontracted services, license fees, and
other external costs. Nonrefundable advance payments for goods and
services that will beused in future research and development
activities are expensed when the activity is performed or when the
goods have been received,rather than when payment is made, in
accordance with ASC 730, <i>Research and Development</i>.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Warrant Liability</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company issued warrants topurchase equity securities in
connection with the issuance or amendment of short-term and
convertible promissory notes. TheCompany accounts for these
warrants as a liability at fair value when the number of shares is
not fixed and determinable incases where warrant pricing
protections in future equity financings are not available to other
common stockholders.Additionally, issuance costs associated with
the warrant liability are expensed as incurred and reflected as
interest expensein the accompanying condensed consolidated
statements of operations. The Company adjusts the liability for
changes in fairvalue until the earlier of the exercise or
expiration of the warrants for any period when pricing protections
in futureequity financings remain in place, or until such time, if
any, as the number of shares to be exercised becomes fixed, atwhich
point the warrants will be classified in stockholders’ (deficit)
equity provided that there are sufficientauthorized and unissued
shares of common stock to settle the warrants and redeem any other
contracts that may requiresettlement in shares of common stock. Any
future change in fair value of the warrant liability, when
outstanding, isrecognized in the consolidated statements of
operations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Premium Debt Conversion Derivatives</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company evaluates all conversion andredemption features
contained in a debt instrument to determine if there are any
embedded derivatives that require separation fromthe host debt
instrument. An embedded derivative that requires separation is
bifurcated from its host debt instrument and a
correspondingdiscount to the host debt instrument is recorded. The
discount is amortized and recorded to interest expense over the
term of thehost debt instrument using the straight-line method
which approximates the effective interest method.&nbsp; The
separated embeddedderivative is accounted for separately on a fair
market value basis. The Company records the fair value changes of a
separatedembedded derivative at each reporting period in the
condensed consolidated statements of operations. The Company
determined thatthe redemption features under the amended short-term
promissory notes and convertible promissory notes qualified as
embedded derivativesand were separated from their debt hosts.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<!-- Field: Page; Sequence: 10; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Income Taxes</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
For the Company, income taxes are accountedfor under the asset and
liability method. Deferred tax assets and liabilities are
recognized for the future tax consequences attributableto
differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax baseand
operating loss and tax credit carryforwards. Deferred tax assets
and liabilities are measured using enacted tax rates expectedto
apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. Deferredtax
assets are reduced by a valuation allowance if it is more likely
than not that some portion or all of the deferred tax assetwill not
be realized.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Net Loss Per Share</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
For the Company, basic loss per shareof common stock is computed by
dividing net loss by the weighted average number of shares of
common stock outstanding during theperiod.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Diluted earnings or loss per share ofcommon stock is computed
similarly to basic earnings or loss per share except the weighted
average shares outstanding are increasedto include additional
shares from the assumed exercise of any common stock equivalents,
if dilutive. The Company’s short-termnotes, convertible promissory
notes, warrants and stock options are considered common stock
equivalents for this purpose. Dilutedearnings is computed utilizing
the treasury method for the warrants and stock options. Diluted
earnings with respect to the short-termnotes and convertible
promissory notes utilizing the if-converted method was not
applicable during the three month periods endedMarch 31, 2018 and
2017 as no conditions required for conversion had occurred during
these periods. No incremental common stockequivalents were included
in calculating diluted loss per share because such inclusion would
be anti-dilutive given the net lossreported for the three month
periods ended March 31, 2018 and 2017.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The following potential common shareswere not considered in the
computation of diluted net loss per share as their effect would
have been anti-dilutive for the threemonth periods ended March 31,
2018 and 2017:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="text-align: justify">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
2018</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
2017</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%">Warrants</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 9%; text-align: right">189,750</td>
<td style="width: 1%; text-align: left">(1)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 9%; text-align: right">597,283</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Stock options</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">365,716</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
<td style="width: 24px"><font style=
"font-size: 10pt">(1)</font></td>
<td style="text-align: justify"><font style="font-size: 10pt">There
are additional potential warrants to be included which will be
known, if and when a qualified financing event greater than $3
million or a change of control transaction occurs in the
future.&nbsp;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Recent Accounting Pronouncements</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In May 2017, the FASB issued ASU2017-09, <i>Compensation - Stock
Compensation (Topic 718):&nbsp;Scope of Modification Accounting
(ASU2016-09)</i>,&nbsp;which provides guidance about which changes
to the terms or conditions of a share-based payment awardrequire an
entity to apply modification accounting in Topic 718. This
pronouncement is effective for annual reporting periodsbeginning
after December 15, 2017. The Company has adopted this standard for
the three months ended March 31, 2018. Theadoption of this standard
did not have any impact on the Company’s consolidated financial
statements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;&nbsp;&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In July 2017, the FASB issued ASU No.2017-11, <i>Earnings Per
Share, Distinguishing Liabilities from Equity and Derivatives and
Hedging</i>, which changes the accountingand earnings per share for
certain instruments with down round features. The amendments in
this ASU should be applied using acumulative-effect adjustment as
of the beginning of the fiscal year or retrospective adjustment to
each period presented and iseffective for annual periods beginning
after December&nbsp;15, 2018 for public business entities,
including interim periods withinthose fiscal years. Early adoption
is permitted. The Company is currently evaluating the requirements
of this new guidance andhas not yet determined its impact on the
Company’s consolidated financial statements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 11; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE4 – Commitments and Contingencies</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Legal</b>&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
From time to time, the Company is subjectto litigation and claims
arising in the ordinary course of business.&nbsp; In May 2017,
NeuroOne received a letter from PMT, theformer employer of Mark
Christianson and Wade Fredrickson.&nbsp; PMT claimed that these
officers had breached their restrictivecovenant obligations with
PMT by virtue of their work for NeuroOne and such officer’s prior
work during employment withthe prior employer, that these officers
had breached their confidentiality and non-disclosure obligations
to PMT and federal andstate law by misappropriating confidential
and trade secret information, and that the Company is responsible
for tortious interferencewith the contracts.&nbsp; The letter
demanded that Mr. Fredrickson (who is no longer with the Company),
Mr. Christianson and NeuroOnecease and desist all competitive
activities, that Mr. Fredrickson step down from his position and
that Mr. Christianson and NeuroOneprovide the former employer
access to NeuroOne’s systems to demonstrate that it is not using
trade secrets or proprietaryinformation nor competing with the
former employer.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
On March 29, 2018, we were served witha complaint filed by PMT
adding the Company, NeuroOne and Mr. Christianson to its existing
lawsuit against Mr. Fredrickson.&nbsp;In the lawsuit, PMT claims
that Mr. Fredrickson and Mr. Christianson breached their
non-competition, non-solicitation and non-disclosureobligations,
breached their fiduciary duty obligations, were unjustly enriched,
engaged in unfair competition, engaged in a civilconspiracy,
tortiously interfered with PMT’s contracts and prospective economic
advantage, and breached a covenant of goodfaith and fair
dealing.&nbsp; Against Mr. Fredrickson, PMT also alleges that he
intentionally or negligently spoliated evidence,made negligent or
fraudulent misrepresentations, misappropriated trade secrets in
violation of Minnesota law, and committed thetort of conversion and
statutory civil theft.&nbsp; Against the Company and NeuroOne, PMT
alleges that the Company and NeuroOnewere unjustly enriched and
engaged in unfair competition.&nbsp; PMT asks the Court to impose a
constructive trust over the sharesheld by Mr. Fredrickson and Mr.
Christianson and to award compensatory damages, equitable relief,
punitive damages, attorneys’fees, costs and interest.&nbsp; The
Company, NeuroOne and Mr. Christianson (who has not worked for PMT
since 2012) intend to defendthemselves vigorously.&nbsp;&nbsp;The
outcome and potential loss related to this matter is unknown as of
March 31, 2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company has no insurance coverageto protect against any losses
that the Company may experience due to this claim. Furthermore, Mr.
Christianson is a key officerand the loss of his services would be
detrimental to the Company’s operations and prospects.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 12; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE5 – Intangibles</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Intangible assets consisted of the followingat March 31, 2018:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="text-align: justify">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
Useful Life</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style="text-align: center">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 72%; text-align: justify">Net Intangibles,
December 31, 2017</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 12%; text-align: center">12-13 Years</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 12%; text-align: right">216,372</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify; padding-bottom: 1.5pt">Less:
amortization</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="text-align: justify; padding-bottom: 1.5pt">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
(4,952</td>
<td style="padding-bottom: 1.5pt; text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 4pt">Net
Intangibles, March 31, 2018</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="text-align: justify; padding-bottom: 4pt">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
211,420</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Amortization expense was $4,952 and $5,007for the three months
ended March 31, 2018 and 2017, respectively.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE6 – Accrued Expenses</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Accrued expenses consisted of the followingat March 31, 2018 and
December 31, 2017:&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style=
"border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
31,</b></font><br />
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style=
"border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31,</b></font><br />
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2017</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="width: 76%; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued&nbsp;license
fees</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="width: 9%; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">120,000</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="width: 9%; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">120,000</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
services</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">868,811</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">600,339</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
issuance costs</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">28,083</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">28,083</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
payroll</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">251,543</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">223,195</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">—
</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
(1)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">254,437</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">—
</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">1,522,874</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">1,021,617</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style=
"font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white">
<tr style="vertical-align: top">
<td style="width: 0.25in"></td>
<td style="width: 0.25in"><font style=
"font-size: 10pt">(1)</font></td>
<td><font style="font-size: 10pt">Accrued expenses include an
obligation to issue stock awards and stock options to
consultantsthat have met vesting requirements as of March 31, 2018
in the amount of $254,437. See Note 10 – Stock-Based
Compensationfor further detail.</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE7 – Short-Term Promissory Notes and Unsecured Loan</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Short-Term Promissory Notes</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In August 2017, the Company’sBoard of Directors (the “Board”)
authorized, and the Company issued short-term unsecured and
interest-freepromissory notes (the “Short-Term Notes”) for
aggregate gross proceeds of $253,000 prior to issuance costs
of$3,030 which were discounted from the Short-Term Notes and were
amortized ratably to interest expense over the original termof the
Short-Term Notes up though November 2017. On November 30, 2017, the
Short-Term Notes were amended to extend thematurity date from
February 18, 2018 to July 31, 2018 and to increase warrant coverage
to 189,750 common stock purchasewarrants (“Original Warrants”). The
Original Warrants had a term of 5 years and an exercise price of
$1.80 andwould have been immediately exercisable upon maturity of
the Short-Term Notes prior to the amendment described below.
TheNovember 30, 2017 amendment resulted in a substantial
modification to the Short-Term Notes and was accounted for under
theprovisions of extinguishment accounting.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Short-Term Noteswere subsequently amended and restated on March
12, 2018 (the “Amended and Restated Short-Term Notes”). The Amended
and Restated Short-Term Notes became convertiblepromissory notes
that bear interest at a fixed rate of 8% per annum and require the
Company to repay the principal andaccrued and unpaid interest
thereon on the maturity date of July 31, 2018 (the “Short-Term Note
Maturity Date”).Pursuant to the terms of each Amended and Restated
Short-Term Note and a consent signed by the Company and each
holder, theOriginal Warrants under the Short-Term Notes were
modified whereby each subscriber received a replacement warrant(the
“Replacement Warrant”) upon the issuance of the Amended and
Restated Short-Term Note, in lieu of theOriginal Warrant. In
addition, each holder was issued an additional warrant (the 
“Additional Warrant”).</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 13; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
If the Company raises more than$3,000,000 in an equity or
equity-linked financing before July 31, 2018 (the “Short-Term Note
QualifiedFinancing”), the outstanding principal and accrued
interest (the “Outstanding Balance”) on the Amended andRestated
Short-Term Notes shall automatically convert into the securities
issued by the Company in the Short-Term NoteQualified Financing
(the “New Round Stock”) based on the greater number of such
securities resulting from either(i) the Outstanding Balance divided
by $1.80 or (ii) the Outstanding Balance multiplied by 1.25,
divided by the price paidper security in the Short-Term Note
Qualified Financing. If a change of control transaction occurs
prior to the earlier of aShort-Term Note Qualified Financing or the
Short-Term Note Maturity Date, the Amended and Restated Short-Term
Noteswould, at the election of the holders of a majority of the
outstanding principal of the Amended and Restated Short-TermNotes,
either become payable on demand as of the closing date of such
transaction or become convertible into shares of commonstock
immediately prior to such transaction at a price per share equal to
the lesser of (i) the per share value of the commonstock as
determined by the Board as if in connection with the granting
ofstock-based compensation or in a private sale to a third party in
an arms’ length transaction or (ii) at the per shareconsideration
to be paid in such transaction. The date of a conversion under a
Short-Term Note Qualified Financing or achange of control
transaction under the terms of the Amended and Restated Short-Term
Notes is referred to herein as the“Conversion Date”.&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Replacement Warrants</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Each Replacement Warrant grants theholder the option to purchase up
to the number of shares of capital stock of the Company equal to
the New Round Stock issuedor issuable upon the conversion of the
Amended and Restated Short-Term Note held by such holder at a per
share exercise priceequal to either (i) the actual per share price
of New Round Stock if the Amended and Restated Short-Term Notes
converted inconnection with a Short-Term Note Qualified Financing
or (ii) the price at which the Amended and Restated Short-Term
Notesconverted in connection with a change of control transaction.
The Replacement Warrants are exercisable commencing on
theConversion Date and expire on November 21, 2021. The exercise
price and number of the shares issuable upon exercising
theReplacement Warrants are subject to adjustment in the event of
any stock dividends and splits, reverse stock
split,recapitalization, reorganization or similar transaction, as
described therein.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Replacement Warrants were deemedto be a free-standing
instrument and were accounted for as a liability given the variable
number of shares issuable inconnection with a possible change of
control conversion event. The Company recorded an initial liability
of $137,722 uponissuance with an offset to extinguishment loss
described further below. The fair value changes of the warrant
liabilityassociated with the Short-Term Notes are recorded at each
reporting date in the condensed consolidated statements
ofoperations which amounted to a benefit of $(2,371) for the three
months ended March 31, 2018. A Monte Carlo simulation modelwas used
to estimate the aggregate fair value of the Replacement Warrants as
of March 31, 2018. Input assumptions used wereas follows: risk-free
interest rate of 2.45 percent; expected volatility of 50 percent;
expected life of 3.64 years; andexpected dividend yield of 0
percent. The underlying stock price used in the analysis was on a
non-marketable basis and wasaccording to a separate independent
third-party valuation analysis since there was no active trading
market for theCompany’s common stock</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Additional Warrants</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Each Additional Warrant grants the holderthe option to purchase up
to the number of shares of capital stock of the Company equal to
the product obtained by multiplying(i) the outstanding principal
amount of the Amended and Restated Short-Term Note held by such
holder and (ii) 0.75; at a per shareexercise price of $1.80. The
Additional Warrants are exercisable commencing on the Conversion
Date and expire on November 21,2021. The exercise price and number
of the shares issuable upon exercising the Additional Warrants are
subject to adjustment inthe event of any stock dividends and
splits, reverse stock split, recapitalization, reorganization or
similar transaction, asdescribed therein.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Additional Warrants were deemedto be a free-standing instrument
and were accounted for as equity as there were no variable terms.
The Additional Warrantsamounted to 189,750 shares as of both the
March 12, 2018 amendment date and as of March 31, 2018 with terms
that largelyparallel the provisions of the Original Warrants except
that the Additional Warrants are exercisable on the Conversion
Dateas opposed to the Short-Term Note Maturity Date and the
expiration date was moved up to November 21, 2021 from July 31,
2023.The fair value differential between the Original Warrants and
the Additional Warrants was a reduction of $22,624. The fairvalue
change was recorded as a reduction to additional paid-in capital in
the accompanying condensed balance sheets and wasincluded as part
of the extinguishment loss discussed further below.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 14; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Premium Conversion Derivative</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Upon the March 2018 amendment, the Short-TermNotes contained a 125%
conversion premium in the event that a Short Term Note Qualified
Financing occurs at a price under $2.25per common share. The
Company determined that the redemption feature under the Short-Term
Notes qualified as an embedded derivativeand was reflected as a
liability in the amount of $49,668 at the time of the March 12,
2018 amendment with a corresponding offsetto extinguishment loss
which is described further below. Subsequent to the amendment, the
embedded derivative is accounted forseparately on a fair market
value basis. The Company recorded the fair value changes of the
premium debt conversion derivativeassociated with the Short-Term
Notes in the condensed consolidated statements of operations for an
expense of $43 for the threemonths ended March 31, 2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Other</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The March 2018 amendment resulted in asubstantial modification to
the Short-Term Notes whereby additional conversion features and
warrant coverage were added. The Companyrecorded the Short-Term
Note amendment under the provisions of extinguishment accounting. A
loss on Short-Term Notes extinguishmentin the accompanying
condensed consolidated statements of operations for the three
months ended March 31, 2018 was recorded inthe amount of $186,220,
which represented the difference between the carrying value of the
Short-Term Notes over the combinedfair values of the Short-Term
Notes, premium conversion derivative, Replacement Warrant and
Additional Warrants on the date ofthe amendment. The fair value
decrease of the Short-Term Notes (inclusive of principal and
interest, non-bifurcated embedded conversionfeature and the
Additional Warrants) relative to its adjusted carrying value at the
time of the amendment was $1,170 which wasrecorded as a reduction
to additional paid-in capital on the accompanying condensed balance
sheets.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Pursuant to the Short-Term Note subscriptionagreement, the Company
is entitled to receive notice in the event a holder elects to sell
or receives a bona fide offer for anyportion of the Short-Term
Notes and associated warrants, and the right to purchase the
Short-Term Notes and associated warrantson the same terms as the
proposed sale or bona fide offer, as applicable, as long as the
Company exercises that right within 15days of receiving written
notice. The Company has granted subscribers indemnification rights
with respect to its representations,warranties, covenants and
agreements under the Short-Term Note subscription agreement.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Unsecured Loans</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
On March 20, 2018, the Company receivedcash proceeds from an
unsecured loan, represented by a promissory note, for $115,000 from
an existing stockholder. The loanis interest free and requires that
the Company repay the principal in full on the earlier to occur of
(i) March 20, 2019 or (ii)the closing of an equity round of
financing of the Company that raises more than $3 million in gross
proceeds. The loan includescustomary events of default.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Additionally, NeuroOne received a $50,000short-term unsecured loan
in November 2016 from the placement agent for its convertible
promissory note financing (see Note 8– Convertible Promissory Notes
and Warrant Agreements). NeuroOne incurred no fees or interest
costs for this temporary loanand it was repaid in full in February
2017.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 15; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE8 – Convertible Promissory Notes and Warrant
Agreements</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
As of<br />
March 31,<br />
2018</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
As of<br />
December 31,<br />
2017</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">
2016 convertible promissory notes, net of discounts</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">1,578,239</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">1,543,652</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; text-indent: -9pt; padding-left: 9pt">
2017 convertible promissory notes, net of discounts</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">753,637</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">504,465</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">
Accrued interest</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
173,213</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
120,223</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">
&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
2,505,089</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
2,168,340</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>2016 Convertible Promissory Notes</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In November 2016 and as amended in June2017, the Board authorized
the Company to issue convertible promissory notes (the 
“ConvertibleNotes”) and common stock purchase warrants (the 
“Warrants”) for aggregate gross proceeds of up to $2.5 millionand
entered into subscription agreements with subscribers (the “2016
Private Placement”). The Company amended theConvertible Notes and
Warrants again on November 20, 2017 to extend the maturity date of
the Convertible Notes from November 21,2017 to July 31, 2018 and to
change the terms of the underlying Warrants that include the
removal of down-round pricing protectionprovisions as described
more fully below.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
As of March 31, 2018, the Companyissued a total of $1,625,120 of
Convertible Notes and Warrants to investors. The Convertible Notes
are unsecured. TheConvertible Notes bear interest at a fixed rate
of 8 percent per annum and require the Company to repay the
principal andaccrued and unpaid interest thereon at the earlier of
July 31, 2018 or the consummation of the next equity or
equity-linkedround of financing resulting in more than $3.0 million
in gross proceeds (a “Qualified Financing”). If aQualified
Financing occurs before July 31, 2018, the outstanding principal
and accrued and unpaid interest on the ConvertibleNotes
automatically converts into the securities issued by the Company in
such financing based on the greater number ofsecurities resulting
from either the outstanding principal and accrued interest on the
Convertible Notes divided by $1.80, orthe outstanding principal and
accrued interest on the Convertible Notes multiplied by 1.25,
divided by the price paid persecurity in the Qualified Financing.
If the Company fails to complete a Qualified Financing by July 31,
2018, the ConvertibleNotes will be immediately due and payable on
such date.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
If a change of control transaction orinitial public offering occurs
prior to a Qualified Financing, the Convertible Notes would, at the
election of the holders ofa majority of the outstanding principal
of the Convertible Notes, either become payable on demand as of the
closing date of suchtransaction, or become convertible into shares
of common stock immediately prior to such transaction at a price
per share equalto the lesser of the per share value as determined
by the Board as if in connection with the grantingof stock based
compensation, or in a private sale to a third party in an
arms-length transaction, or at the per share considerationto be
paid in such transaction. Change of control means a merger or
consolidation with another entity in which the Company’
sstockholders do not own more than 50 percent of the outstanding
voting power of the surviving entity or the disposition of allor
substantially all of the assets of the Company.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Prior to the June 2017 amendment, theWarrants granted holders the
option to purchase either (i) if exercised after conversion of the
Convertible Notes, the numberof shares equal to the number of
shares received by the holders upon the conversion of the
Convertible Notes, or (ii) if exercisedprior to conversion of the
Convertible Notes, the number of shares of common stock equal to
the outstanding principal and accruedinterest on the Convertible
Note held by such warrant holder divided by $1.80. The Warrants
were immediately exercisable on thedate of issuance and expired on
November 21, 2021. In June 2017, however, the Company amended the
terms of the Warrants underthe Convertible Notes to be exercisable
only in the event of conversion of the outstanding principal and
accrued interest on therelated Convertible Notes. The amount of
warrant shares to be issued are now contingent and are based on the
number of sharesof common stock received by the holder of the
Convertible Notes upon conversion of such holder’s Convertible
Notes, andat an exercise price equal to the same price per share of
the securities issued in the Qualified Financing. The Warrants
expireon November 21, 2021 in the event of a Qualified Financing or
expire unissued if the notes have not been converted.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 16; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Warrants were deemed to be a free-standinginstrument and were
accounted for as a liability given the variable number of shares
issuable in connection with a possible changeof control conversion
event. A Monte Carlo simulation model was used to estimate the
aggregate fair value of the Warrants. Inputassumptions used were as
follows: risk-free interest rate of 2.45 and 2.08 percent as of
March 31, 2018 and December 31, 2017,respectively; expected
volatility of 50 percent as of March 31, 2018 and December 31,
2017; expected life of 3.64 and 3.89 yearsas of March 31, 2018 and
December 31, 2017, respectively; and expected dividend yield of 0
percent as of March 31, 2018 and December31, 2017. The underlying
stock price used in the analysis was on a non-marketable basis and
was according to a separate independentthird-party valuation
analysis since there was no active trading market for the Company’s
common stock.&nbsp;The ConvertibleNote proceeds assigned to the
Warrants were zero and $182,693 during the three months ended March
31, 2018 and 2017, respectively,which represented their fair value
at issuance, and were discounted from the Convertible Notes and
reflected as a warrant liability.The discount was amortized to
interest expense over the original term of the Convertible Notes
using the straight-line methodwhich approximates the effective
interest method. The amortization expense was zero and $118,862 for
the three months ended March31, 2018 and 2017, respectively. The
Company also recorded the fair value changes of the warrant
liability associated with theConvertible Notes in the condensed
consolidated statements of operations which amounted to a benefit
of $(130,976) and $(215)for the three months ended March 31, 2018
and 2017, respectively.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The November 2017 amendment resulted ina substantial modification
to the original Convertible Notes whereby the maturity date was
extended, and the terms associatedwith the Warrants were revised.
The fair value of the underlying convertible notes was $97,223
lower than the carrying value ofthe Convertible Notes on the date
of the modification. The $97,223 difference was recorded as a
discount to the debt and is beingamortized over the amended term of
the Convertible Notes. The amortization recorded during the three
months ended March 31, 2018and 2017 was $34,585 and zero,
respectively.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
At the time of their issuance, the ConvertibleNotes contained a
125% conversion premium in the event that a Qualified Financing
occurs at a price under $2.25 per common share.The Company
determined that the redemption feature under the Convertible Notes
qualified as an embedded derivative and was separatedfrom its debt
host. The bifurcation of the embedded derivative from its debt host
resulted in a discount to the Convertible Notesin the amount of
zero and $72,732 during the three months ended March 31, 2018 and
2017, respectively. The discount was beingamortized to interest
expense over the original term of the Convertible Notes using the
straight-line method which approximatesthe effective interest
method. The amortization expense was zero and $47,318 for the three
months ended March 31, 2018 and 2017,respectively. The embedded
derivative is accounted for separately on a fair market value
basis. The Company recorded the fairvalue changes of the premium
debt conversion derivative associated with the Convertible Notes in
the condensed consolidated statementsof operations for an expense
of $2,666 and $183 for the three months ended March 31, 2018 and
2017, respectively.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In connection with the Convertible Notes,the Company incurred
issuance costs in the amount of $151,915, which included (i) a
placement agent cash fee, which was $113,610for the Convertible
Notes issued through June 19, 2017 (ii) the obligation to issue a
warrant to the placement agent (the “placementagent warrant”) which
will have an exercise price of $2.00 per share of common stock and
had a total fair value of $4,855on date of Convertible Note
issuance, and (iii) legal expenses of $33,450. The placement agent
warrant is issuable at the timethe private placement transaction
closes which has not occurred as of March 31, 2018. The placement
agent warrant will be immediatelyexercisable on the date of
issuance and will expire five years following the date of issuance.
The placement agent is to receivea placement agent warrant to
purchase shares of common stock in an amount equal to 8% of the
common stock (or common stock equivalents)purchased by investors in
the private placement transaction. As of March 31, 2018 and
December 31, 2017, the Company has an obligationto issue a
placement agent warrant for the purchase of approximately 63,000
shares of common stock. The Company recorded an issuancecost
discount to the Convertible Notes in the amount of zero and $16,645
during the three months ended March 31, 2018 and 2017,respectively,
of which zero and $12,361 was amortized to interest expense during
the three months ended March 31, 2018 and 2017,respectively. The
balance of the issuance costs in the amount of zero and $15,803 was
attributed to the Warrants and was immediatelyrecorded as interest
expense upon issuance during the three months ended March 31, 2018
and 2017, respectively.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 17; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>2017 Convertible Notes</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
On October 4, 2017, the Company initiallyentered into a
subscription agreement (with certain investors (the “Subscribers”),
pursuant to which the Company,in a private placement (the “Private
Placement”), agreed to issue and sell to the Subscribers 8%
convertible promissorynotes (each, a “Note” and collectively, the 
“2017 Convertible Notes”) and warrants (the “New Warrants”)to
purchase shares of the Company’s capital stock in the event of a
conversion event. The number of shares and pricing pershare of the
New Warrants are based on the underlying conversion event and are
exercisable for five years commencing on the triggeringconversion
event. In November 2017, the Board approved an increase in the
authorized subscription from $1,000,000 to $1,500,000.The
subscription agreement and the 2017 Convertible Notes were amended
on December 14, 2017 to move up the maturity date fromOctober 4,
2022 to December 31, 2018, remove subordination provisions and
simplify the conversion provision in the event of aqualified
financing as described more fully below. In May 2018, the Board
approved an increase in the authorized subscriptionfrom $1,500,000
to $2,000,000 and extended the offering period from five months to
eight months.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The initial closing of the Private Placementwas consummated on
October 4, 2017, and the Company entered into additional
subscription agreements and issued 2017 ConvertibleNotes in an
aggregate principal amount of $1,140,000 to the Subscribers through
March 31, 2018. The Company may conduct any numberof additional
closings so long as the final closing occurs on or before the
eight-month anniversary of the initial closing dateand the amount
does not exceed $2,000,000 or a higher amount determined by the
Board. See Note 13 – SubsequentEvents for closings that occurred
after March 31, 2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The 2017 Convertible Notes bearinterest at a fixed rate of 8% per
annum and require the Company to repay the principal and accrued
and unpaid interestthereon on December 31, 2018 (the “2017
Convertible Notes Maturity Date”). If the Company consummates an
equityround of financing resulting in more than $3 million in gross
proceeds before December 31, 2018 (the “2017 ConvertibleNotes
Qualified Financing”), the outstanding principal and accrued and
unpaid interest on the 2017 Convertible Notesshall automatically
convert into the securities issued by the Company in the 2017
Convertible Notes Qualified Financing equalto the outstanding
principal and accrued interest on the 2017 Convertible Notes
divided by 80% of the price per share of thesecurities issued by
the Company in the 2017 Convertible Notes Qualified Financing. The
New Warrants also become exercisableupon a 2017 Convertible Notes
Qualified Financing for an amount of shares equal to the number of
shares received by theholder in the 2017 Convertible Notes
Qualified Financing at the same price per share of the securities
issued in the 2017Convertible Notes Qualified Financing.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Prior to the December 2017 amendment,if the Company had raised more
than $3,000,000 in an equity financing before October 4, 2022, the
outstanding principal and accruedand unpaid interest on the 2017
Convertible Notes would have automatically converted into the
securities issued by the Companyin such financing based on the
greater number of such securities resulting from either (i) the
outstanding principal and accruedinterest on the 2017 Convertible
Notes divided by $2.25 or (ii) the outstanding principal and
accrued interest on the 2017 ConvertibleNotes multiplied by 1.25,
divided by the price paid per security in such financing. The New
Warrants would have also become exercisablein conjunction with the
2017 Convertible Notes Qualified Financing.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Lastly, if a change of controltransaction occurs prior to the
earlier of a 2017 Convertible Notes Qualified Financing or the 2017
ConvertibleNotes Maturity Date, the 2017 Convertible Notes would,
at the election of the holders of a majority of the
outstandingprincipal of the 2017 Convertible Notes, either become
payable on demand as of the closing date of such transaction,
orbecome convertible into shares of common stock immediately prior
to such transaction at a price per share equal to the lesserof (i)
the per share value of the common stock as determined by the Board
as if in connection with the grantingof stock based compensation or
in a private sale to a third party in an arms-length transaction or
(ii) at the per shareconsideration to be paid in such transaction.
Change of control means a merger or consolidation with another
entity in whichthe Company’s stockholders do not own more than 50%
of the outstanding voting power of the surviving entity or
thedisposition of all or substantially all of the Company’s assets.
The New Warrants also become exercisable upon a changeof control
transaction for an amount of shares equal to the number of shares
received by the holder upon conversion inconnection with such
transaction at the same price per share that the 2017 Convertible
Notes converted in the change ofcontrol transaction.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 18; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The December 2017 amendment resulted ina substantial modification
to the original 2017 Convertible Notes whereby the maturity date
was moved up to December 2018 fromOctober 2022 and the terms
associated with the embedded features were revised as described
previously. The fair value of the underlyingConvertible Notes was
$27,371 lower than the face amount of the 2017 Convertible Notes.
The $27,371 difference was recorded asa discount to the debt and is
being amortized over the amended term of the 2017 Convertible
Notes. The amortization recorded duringthe three months ended March
31, 2018 was $6,432.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The 2017 Convertible Notes contain aconversion discount in the
event of a 2017 Convertible Notes Qualified Financing to equal the
outstanding principal and accruedinterest on the 2017 Convertible
Notes divided by 80% of the price per share of the securities
issued by the Company in the 2017Convertible Notes Qualified
Financing. The embedded feature qualified as an embedded derivative
and was separated from its debthost. The bifurcation of the
embedded derivative from its debt host resulted in a discount to
the 2017 Convertible Notes in theamount of $91,298 for the
convertible debt issued during the three months ended March 31,
2018. The discount is being amortizedto interest expense over the
term of the 2017 Convertible Notes using the straight-line method
which approximates the effectiveinterest method. The amortization
expense was $27,021 for the three months ended March 31, 2018. The
embedded derivative is accountedfor separately on a fair market
value basis. The Company recorded the fair value changes of the
premium debt conversion derivativeassociated with all of the 2017
Convertible Notes in the condensed consolidated statements of
operations which amounted to anexpense of $1,323 for the three
months ended March 31, 2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The New Warrants were deemed to bea free-standing instrument and
were accounted for as a liability given the variable number of
shares issuable inconnection with a change of control conversion
event. A Monte Carlo simulation model was used to estimate the
aggregate fairvalue of the New Warrants. Input assumptions used
were as follows: risk-free interest rate of 2.57 and 2.22 percent
as ofMarch 31, 2018 and December 31, 2017, respectively; expected
volatility of 50 percent as of March 31, 2018 and December 31,2017;
expected life of 5.21 and 5.38 years as of March 31, 2018 and
December 31, 2017, respectively; and expected dividendyield of 0
percent as of March 31, 2018 and December 31, 2017. The underlying
stock price used in the analysis was on anon-marketable basis and
was according to a separate independent third-party valuation
analysis as there has been verylimited trading with the Company’s
common stock since the Acquisition on July 20, 2017. The 2017
Convertible Noteproceeds assigned to the New Warrants were $238,864
during the three month period ended March 31, 2018, which
representedtheir fair value at issuance and were discounted from
the 2017 Convertible Notes and reflected as a warrant liability.
Thediscount is being amortized to interest expense over the term of
the 2017 Convertible Notes using the straight-line methodwhich
approximates the effective interest method. The amortization
expense was $70,505 for the three month period ended March31, 2018.
The Company also recorded the fair value changes of the warrant
liability associated with &nbsp;all of the 2017Convertible Notes in
the condensed consolidated statements of operations which amounted
to an expense of $9,355 for the threemonths ended March 31,
2018.&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
In connection with the 2017 ConvertibleNotes, the Company incurred
original cost of issuance in the amount of $5,283 which consisted
of legal costs and was recorded asan issuance cost discount to the
2017 Convertible Notes, of which $375 was amortized to interest
expense during the three monthsended March 31, 2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>2016 and 2017 Convertible Note SubscriptionAgreements</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Pursuant to the subscription agreementsentered into in connection
with the 2016 Private Placement and the Private Placement, the
Company is entitled to receive noticein the event a holder elects
to sell or receives a bona fide offer for any portion of the
Convertible Notes and associated Warrantsor any portion of the 2017
Convertible Notes or New Warrants, as applicable, and the right to
purchase the Convertible Notes andassociated Warrants or the 2017
Convertible Notes and associated New Warrants on the same terms as
the proposed sale or bona fideoffer, as applicable, as long as the
Company exercises that right within 15 days of receiving written
notice. The Company hasgranted the subscribers indemnification
rights with respect to its representations, warranties, covenants
and agreements underthe respective subscription agreements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 19; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE9 – Investment Banker Fee</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Investment Banker Fee</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
NeuroOne paid a $50,000 non-refundablefee to an investment banker
in December 2016 to raise equity financing. NeuroOne subsequently
concluded that the investment bankerwas not expected to raise any
equity and therefore expensed the fee in March 2017.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE10 – Stock-Based Compensation</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
NeuroOne formally adopted an equity incentiveplan (“the 2016 Plan”)
on October 27, 2016 which was subsequently adopted by the Company
upon completion of the Acquisition.In addition, the Company adopted
a 2017 Equity Incentive Plan (the “2017 Plan”) on April 17, 2017.
The 2016 and 2017Plans provide for the issuance of restricted
shares and stock options to employees, directors, and consultants
of the Company.The Company reserved 2,292,265 shares of common
stock (as adjusted for the exchange ratio in connection with the
Acquisition) forissuance under the 2016 and 2017 Plans on a
combined basis. The Company began granting stock options and
restricted stock awardsin the second quarter of 2017, under the
2016 Plan. During the three month periods ended March 31, 2018 and
2017, no stock optionsor restricted stock award grants were
formally issued. See stock-based award liability section below for
stock-based award grantscommitted, but not formally issued as of
March 31, 2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
During the three months ended March 31,2018 and 2017, there was no
vesting of formally issued stock options or restricted stock
awards. No stock options were forfeitedduring the three months
ended March 31, 2018 and 2017. As of March 31, 2018, 1,711,096
shares were available for future issuanceon a combined basis under
the 2016 and 2017 Plans.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
There was no unrecognized stock-basedcompensation cost for stock
options and restricted common stock as of March 31, 2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Stock-Based Award Liabilities</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
As of March 31, 2018, the Company hada formal obligation to issue
future restricted common stock and common stock options relating to
two consulting agreements. Theestimated liability associated with
the vested portions of these awards was recorded in accrued
expenses in the accompanying condensedconsolidated balance sheets
as of March 31, 2018. The corresponding stock-based services
expense related to the stock-based awardliability was included in
general and administrative and research and development costs as
follows in the accompanying condensedstatements of operations:</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td nowrap="nowrap" style="font-weight: bold">&nbsp;</td>
<td colspan="2" nowrap="nowrap" style=
"font-weight: bold; text-align: center">Three Months<br />
Ended</td>
<td nowrap="nowrap" style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td nowrap="nowrap">&nbsp;</td>
<td nowrap="nowrap" style=
"font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" nowrap="nowrap" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
March 31,<br />
2018</td>
<td nowrap="nowrap" style=
"padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 88%; text-align: left">General and
administrative</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">252,000</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1.5pt">Research and
development</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
2,437</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 4pt">Total stock-based
compensation</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
254,437</td>
<td style="padding-bottom: 4pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
A total of up to 250,000 shares ofcommon stock was committed as a
result of one consulting agreement for investor relation services
executed in February 2018, butnone of the underlying shares of
common stock were issued as of March 31, 2018. The portion of the
stock award that had met performancevesting conditions as of March
31, 2018 amounted to 100,000 common shares and were issued on April
26, 2018. The amount of compensationexpense totaling $252,000
related to the vested common shares was based on the fair value of
the underlying common stock at pointof vesting which was $2.52 per
share on a non-marketable basis. The common stock fair value was
according to a separate independentthird-party valuation analysis
since there was no active trading market for the Company’s common
stock. The remaining 150,000shares of the stock award will vest and
be issued in 50,000 share quarterly tranches beginning in May 2018.
The first 50,000 trancheof shares was issued on May 7, 2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 20; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Additionally, the Company recorded stock-basedservices expense
related to unissued stock options associated with a second
consulting agreement whereby the number of option sharesand pricing
will not be set until the occurrence of the award date which is
defined as the earlier to occur of a public offering,qualified
financing, or June 30, 2018. The number of option shares under the
agreement is based on a $3,000 monthly compensationamount divided
by the fair value of the underlying common stock on the award date.
The exercise price will also be set at thefair value of the
underlying common stock on the award date. The liability associated
with the unissued options was based on anoption share equivalent
estimate that reflects the portion of the award where performance
vesting conditions have been met asof March 31, 2018 and was based
on the fair value of the Company’s common stock on March 31, 2018
as the award date hasnot occurred. The common stock fair value on
March 31, 2018 was $2.30 per share and was determined based on a
separate independentthird-party valuation analysis since there was
no active trading market for the Company’s common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The weighted-average assumptions usedin the Black-Scholes
option-pricing model are as follows for the stock- option liability
during the three month periods endedMarch 31, 2018:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
2018</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 88%; text-align: left">Expected stock price
volatility</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 9%; text-align: right">47.8</td>
<td style="width: 1%; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Expected life of options (years)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Expected dividend yield</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">0</td>
<td style="text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Risk free interest rate</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2.6</td>
<td style="text-align: left">%</td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Upon the issuance of all of theunissued options associated with the
stock-based award liabilities, the estimated number of shares
available for futureissuance as of March 31, 2018 would be reduced
from 1,711,096 shares to 1,704,574 as a result of the potential
stock optionissuance under the second consulting agreement. The
250,000 shares of common stock issuable under the February
2018consulting agreement were not eligible for issuance under
either of the 2016 or 2017 Plans as the consulting contract was
notwith an individual. See Note 12 - Stockholders’ Deficit for
additional information.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE11 – Income Taxes</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The effective tax rate for the three monthsended March 31, 2018 and
2017 was zero percent. As a result of the analysis of all available
evidence as of&nbsp;March 31,
2018&nbsp;and&nbsp;December&nbsp;31,2017, the Company recorded a
full valuation allowance on its net deferred tax assets.
Consequently, the Company reported&nbsp;no&nbsp;incometax benefit
during the&nbsp;three months ended&nbsp;March 31, 2018 and 2017. If
the Company’s assumptions change and theCompany believes that it
will be able to realize these deferred tax assets, the tax benefits
relating to any reversal of the valuationallowance on deferred tax
assets will be recognized as a reduction of future income tax
expense.&nbsp;&nbsp;If the assumptionsdo not change, each period
the Company could record an additional valuation allowance on any
increases in the deferred tax assets.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
On December 22, 2017, the Tax Cuts andJobs Act of 2017 was signed
into law making significant changes to the U.S. tax code. Changes
affecting the Company’s consolidatedfinancial statements include,
but are not limited to, a U.S. federal corporate tax rate decrease
from 35% to 21% effective fortax years beginning after December 31,
2017. The Company has adjusted the disclosure amounts related to
deferred tax assets andthe valuation allowance recorded to reflect
the new federal corporate tax rates.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 21; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
NeuroOne Medical Technologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
Notes to Condensed Consolidated FinancialStatements, continued</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
(unaudited)</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE12 – Stockholders’ Deficit</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Common Stock</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company has 100,000,000 shares ofcommon stock authorized, par
value $0.001 per share, of which 7,864,994 shares were issued and
outstanding at March 31, 2018 andDecember 31, 2017. In connection
with the February 2018 consulting contract discussed in Note 10 –
Stock-based Compensation,up to 250,000 shares of common stock are
issuable under the contract. Upon issuance, these shares are
subject to restrictionspursuant to the provisions of Rule&nbsp;144.
On April 26, 2018 and May 7, 2018, 100,000 and 50,000 shares of
common stock wereissued under the contract, respectively, and
subject to the restrictions under the provisions of Rule 144.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid">
<b>NOTE13 – Subsequent Events</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>2017 Convertible Notes</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The Company issued additional 2017 ConvertibleNotes and New
Warrants to investors for aggregate gross proceeds of $350,000 from
April 13, 2018 to May 8, 2018. &nbsp;The additionalconvertible
notes and warrants issued have identical terms to the 2017
Convertible Notes and New Warrants disclosed in Note 8- Convertible
Promissory Notes and Warrant Agreements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Additionally, on May 8, 2018, theBoard approved an increase in the
maximum amount of aggregate 2017 Convertible Notes offered from
$1,500,000 to$2,000,000.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>Issuance of Common Stock</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Between April 26, 2018 and May 7, 2018,the Company issued 150,000
shares of common stock to an investor relations firm in
consideration for consulting services.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<!-- Field: Page; Sequence: 22; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Item 2. Management’s Discussion and Analysis of
FinancialCondition and Results of Operations</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">
<i>The followingdiscussion of our financial condition and results
of operations should be read in conjunction with the financial
statements andnotes included in Part I “Financial Information”,
Item I “Financial Statements” of this Quarterly Reporton Form 10-Q
(the “Report”) and the audited financial statements and related
footnotes included in our Annual Reporton Form 10-K for the year
ended December 31, 2017.</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<i>&nbsp;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Forward-Looking Statements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
<i>Certain statementscontained in this Report are not statements of
historical fact and are forward-looking statements within the
meaning of Section27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
(the “ExchangeAct”). Forward-looking statements give current
expectations or forecasts of future events or our future financial
or operatingperformance. We may, in some cases, use words such as 
“anticipate,” “believe,” “could,” “estimate,”“expect,” “intend,” 
“may,” “plan,” “potential,” “predict,”“project,” “should,” “will,” 
“would” or the negative of those terms, and similarexpressions that
convey uncertainty of future events or outcomes to identify these
forward-looking statements.</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
These forward-lookingstatements reflect our management’s beliefs
and views with respect to future events, are based on estimates and
assumptionsas of the date of this Report and are subject to risks
and uncertainties, many of which are beyond our control, that could
causeour actual results to differ materially from those in these
forward-looking statements. We discuss many of these risks in
greaterdetail under Part I, Item 1A “Risk Factors” in our Annual
Report on Form 10-K for the year ended December 31, 2017and
subsequent reports filed with or furnished to the Securities and
Exchange Commission (the “SEC”). Moreover, weoperate in a very
competitive and rapidly changing environment. New risks emerge from
time to time. It is not possible for ourmanagement to predict all
risks, nor can we assess the impact of all factors on our business
or the extent to which any factor,or combination of factors, may
cause actual results to differ materially from those contained in
any forward-looking statementswe may make. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Any forward-lookingstatement made by us in this Report speaks only
as of the date hereof or as of the date specified herein. We
undertake no obligationto publicly update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, exceptas may be required by applicable
laws or regulations.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Overview</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
We were originallyincorporated in the State of Nevada on August 20,
2009 as Original Source Entertainment, Inc. (“OSE”). OSE was
originallyformed to license songs to the television and movie
industry. From our inception and prior to the acquisition of
NeuroOne, Inc.(“NeuroOne”) on July 20, 2017 (the “Acquisition”), as
described more fully below, our operations have beenprimarily
limited to organizational, start-up, and capital formation
activities. Upon completion of the Acquisition, more fullydescribed
below, our operations consist of the development of comprehensive
neuromodulation cEEG and sEEG monitoring, ablation,and brain
stimulation solutions to diagnose and treat patients with epilepsy,
Parkinson’s disease, dystonia, essential tremors,and other brain
related disorders. Our cortical strip technology under development
has only been used by the Mayo clinic in fivepatients for research
purposes and has not been tested in any clinical trials. We are
based in Eden Prairie, Minnesota.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The Acquisition wasaccounted for as a capital transaction, or
reverse recapitalization. As a result, the financial information
contained in this Reportreflect solely the operations of our
wholly-owned subsidiary, NeuroOne, and its predecessor NeuroOne LLC
(the “LLC”).</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p>
<!-- Field: Page; Sequence: 23; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
To date, our primaryactivities have been limited to, and our
limited resources have been dedicated to, performing business and
financial planning,raising capital, recruiting personnel,
negotiating with business partners and the licensors of our
intellectual property and conductingresearch and development
activities. Our cortical strip, grid electrode and depth electrode
technology is still under development,we do not yet have regulatory
approval in any jurisdiction to sell any products and we have not
generated any revenue.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
We have incurredlosses since inception. As of March 31, 2018, we
had an accumulated deficit of $6.7 million, primarily as a result
of expensesincurred in connection with our research and development
programs and from general and administrative expenses associated
withour operations. We expect to continue to incur significant
operating expenses and net losses for the foreseeable future.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
We do not expect togenerate revenue from product sales unless and
until we obtain marketing authorization to sell our cortical strip,
grid electrodeand depth electrode technology from applicable
regulatory authorities.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Our source of cashto date has been proceeds from the issuances of
notes and warrants and unsecured loans. See “—Liquidity and
CapitalResources—Historical Capital Resources” below.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
At March 31, 2018,we had $25,198 in cash deposits. Our existing
cash and cash equivalents will not be sufficient to fund our
operating expensesin 2018. We need to obtain substantial additional
funding in connection with our continuing operations through public
or privateequity or debt financings or other sources, which may
include collaborations with third parties. However, we may be
unable toraise additional funds when needed on favorable terms or
at all. Our failure to raise such capital as and when needed would
havea negative impact on our financial condition and our ability to
develop and commercialize our cortical strip, grid electrode
anddepth electrode technology and future products and our ability
to pursue our business strategy. See “—Liquidity andCapital
Resources—Funding Requirements and Outlook” below.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Acquisition</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
On July 20, 2017, we entered into a Merger Agreement with NeuroOne
and OSOK Acquisition Company to acquireNeuroOne (the “Merger
Agreement”). The transactions contemplated by the Merger Agreement
were consummated on July20, 2017 and, pursuant to the terms of the
Merger Agreement, (i)&nbsp;all outstanding shares of common stock
of NeuroOne (“NeuroOneShares”) were exchanged for shares of the
Company’s common stock (“Common Stock”), based on the exchangeratio
of 17.0103706 shares of Common Stock, for every one NeuroOne Share,
which totaled 6,291,994 shares of Common Stock, forall of the
then-outstanding NeuroOne Shares, (ii)&nbsp;all NeuroOne options
were replaced with options (“Company Options”)based on the Exchange
Ratio, with corresponding adjustments to their respective exercise
prices, (iii) all NeuroOne warrants werereplaced with warrants to
purchase Common Stock of the Company (“Company Warrants”) and (iv)
we assumed the outstandingconvertible promissory notes of NeuroOne.
Accordingly, we acquired 100% of NeuroOne in exchange for the
issuance of shares ofour Common Stock and NeuroOne became our
wholly-owned subsidiary. Our sole business is the business of
NeuroOne. Our management’sdiscussion and analysis below is based on
the financial results of NeuroOne. Except as otherwise indicated
herein, all share andper share information in this “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations”section gives retroactive effect to the exchange of
NeuroOne Shares, NeuroOne Options and NeuroOne Warrants for shares
of CommonStock, Company Options and Company Warrants, respectively,
in the Acquisition, as well as the corresponding exercise price
adjustmentsfor such Company Options.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<!-- Field: Page; Sequence: 24; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">
<b>FinancialOverview</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Revenue</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
To date, we have notgenerated any revenue. We do not expect to
generate revenue unless or until we develop, obtain regulatory
approval for and commercializeour cortical strip, grid electrode
and depth electrode technology. If we fail to complete the
development of our cortical strip,grid electrode and depth
electrode technology, or any other product candidate we may pursue
in the future, in a timely manner,or fail to obtain regulatory
approval, we may never be able to generate any revenue.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>General and Administrative</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
General and administrativeexpenses consist primarily of
personnel-related costs including stock-based compensation for
personnel in functions not directlyassociated with research and
development activities. Other significant costs include legal fees
relating to corporate matters,intellectual property costs,
professional fees for consultants assisting with regulatory,
clinical, product development, financialmatters and product costs.
We anticipate that our general and administrative expenses will
significantly increase in the futureto support our continued
research and development activities, potential commercialization of
our cortical strip, grid electrodeand depth electrode technology,
if approved, and the increased costs of operating as a public
company. These increases will includeincreased costs related to the
hiring of additional personnel and fees for legal and professional
services, as well as other public-companyrelated costs.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Research and Development</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Research and developmentexpenses consist of expenses incurred in
performing research and development activities in developing our
cortical strip, gridelectrode and depth electrode technology.
Research and development expenses include compensation and benefits
for research anddevelopment employees including stock-based
compensation, overhead expenses, cost of laboratory supplies,
clinical trial and relatedclinical manufacturing expenses, costs
related to regulatory operations, fees paid to consultants and
other outside expenses.Research and development costs are expensed
as incurred and costs incurred by third parties are expensed as the
contracted workis performed.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
We expect our researchand development expenses to significantly
increase over the next several years as we develop our cortical
strip, grid electrodeand depth electrode technology and conduct
preclinical testing and clinical trials and will depend on the
duration, costs andtiming to complete our preclinical programs and
clinical trials.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Interest Expense</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Interest expense primarilyconsists of amortized discount costs and
interest costs related to our Series 1 Notes (as defined below),
Series 2 Notes (as definedbelow) and Series 3 Notes (as defined
below). The Series 1 Notes, Series 2 Notes, and Series 3 Notes bear
interest at a fixedrate of 8% per annum, compounding annually.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Net change in fair value for thewarrant liability and premium
conversion derivatives</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The net change in fairvalue for the warrant liability and premium
conversion derivatives includes the change in the fair value of
warrant liability andthe premium conversion derivatives during the
particular period while the warrant liability and the premium
conversion derivativesare outstanding.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p>
<!-- Field: Page; Sequence: 25; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Results of Operations</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Comparison of the Three Months Ended March 31, 2018
and2017</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The following tablesets forth the results of operations for the
three-months ended March 31, 2018 and 2017, respectively.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="10" style=
"border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the three months ended</b></font><br />
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
31,</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style=
"border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2018</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style=
"border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2017</b></font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="border-bottom: black 1.5pt solid">
<p style=
"font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Period to</b></p>
<p style=
"font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Period</b></p>
<p style=
"font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">
<b>Change</b></p>
</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
expenses:</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: right; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: right; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td colspan="2" style="text-align: right; line-height: 107%">
&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style=
"width: 64%; padding-left: 10pt; text-indent: -10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="width: 9%; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">992,435</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="width: 9%; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">444,016</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
<td style="width: 1%; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style="width: 9%; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">548,419</font></td>
<td style="width: 1%; line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style=
"padding-left: 10pt; text-indent: -10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">105,045</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">72,041</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">33,004</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style=
"padding-left: 10pt; text-indent: -10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
operating expenses</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">1,097,480</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">516,057</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">581,423</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style=
"padding-left: 10pt; text-indent: -10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
from operations</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,097,480</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(516,057</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(581,423</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style=
"padding-left: 10pt; text-indent: -10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(193,034</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(213,550</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">20,516</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style=
"padding-left: 10pt; text-indent: -10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
change in fair value for the warrant liability and premium
conversion derivatives</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">119,960</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">32</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="text-align: right; line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">119,928</font></td>
<td style="line-height: 107%">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
<td style=
"padding-left: 10pt; text-indent: -10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
on short-term notes extinguishment</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(186,220</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">—
&nbsp;</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 1.5pt solid; line-height: 107%">
&nbsp;</td>
<td style=
"border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(186,220</font></td>
<td style="line-height: 107%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white">
<td style=
"padding-left: 10pt; text-indent: -10pt; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
loss</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,356,774</font></td>
<td style="line-height: 107%; padding-bottom: 4pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(729,575</font></td>
<td style="line-height: 107%; padding-bottom: 4pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
<td style="line-height: 107%">&nbsp;</td>
<td style="border-bottom: black 4.5pt double; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td>
<td style=
"border-bottom: black 4.5pt double; text-align: right; line-height: 107%">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(627,199</font></td>
<td style="line-height: 107%; padding-bottom: 4pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>General and administrative expenses</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
General and administrativeexpenses were $1.0 million for the three
months ended March 31, 2018, compared to $0.4 million for the three
months ended March31, 2017. The increase was primarily due to an
increase in stock-based compensation associated with a consulting
contract of $0.3million related to fund raising, and legal and
accounting expenses of $0.3 million primarily related to public
company relatedcosts.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>&nbsp;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<i>Research and development expenses</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Research and developmentexpenses were $0.1 million for the three
months ended March 31, 2018, compared to $72,041 for the three
months ended March 31,2017. The increase was primarily due to an
increase in salary-related expenses, stock-based compensation
expense of $2,437 relatedto a consulting contract, and development
materials and supplies to support the increased level of
development activities duringthe first quarter of 2018.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>&nbsp;Interest expense</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
Interest expense, forthe three months ended March 31, 2018 was $0.2
million consisting of interest expense of $54,116 and amortization
of debt discountcosts of $0.1 million related to the Series 1
Notes, Series 2 Notes and Series 3 Notes described further below.
Interest expense,for the three months ended March 31, 2017 was $0.2
million consisting of interest expense and amortization of debt
issuance costsof $0.2 million related to the Series 1 Notes and
other interest expense of $1,318.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>Net change in fair value for the warrantliability and premium
conversion derivatives</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<i>&nbsp;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The net changein fair value for the warrant liability and premium
conversion derivatives for the three months ended March 31, 2018
and 2017was income of $0.1 million and $32, respectively. The
change is due primarily to fluctuations in our Common Stock fair
value andthe number of potential shares of Common Stock issuable
upon conversion of the underlying Series 1 Notes, Series 2 Notes
and Series3 Notes.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<i>&nbsp;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<i>Loss on short-term notes extinguishment</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Non-cash loss on short-termnotes extinguishment for the three
months ended March 31, 2018 was $0.2 million. There were no note
extinguishments in the comparableprior year period. The Series 2
Notes were amended in March 2018. The amendment for the Series 2
Notes added additional embeddedconversion features and warrant
coverage. As a result of the modifications made to the Series 2
Notes, we accounted for the amendmentas a note extinguishment.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 26; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>&nbsp;</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Liquidity and Capital Resources</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Historical Capital Resources</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
As of March 31, 2018,our principal source of liquidity consisted of
cash deposits of $25,198. We have not generated any revenue, and we
anticipatethat we will continue to incur losses for the foreseeable
future. We anticipate that our expenses will increase
substantiallyas we develop our cortical strip, grid electrode and
depth electrode technology and pursue pre-clinical testing and
clinical trials,seek regulatory approvals, contract to manufacture
any products, establish our own sales, marketing and distribution
infrastructureto commercialize our cortical strip, grid electrode
and depth electrode technology under development, if approved, hire
additionalstaff, add operational, financial and management systems
and operate as a public company.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Our source of cashto date has been proceeds from the issuances of
notes, warrants and unsecured loans, the terms of which are further
describedbelow. See “—Funding Requirements and Outlook” below for
the outstanding balances on our convertible notes.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<u>Series 3 Notes and Warrants</u></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
From October2017 to May 2018, the Company issued convertible notes
(the “Series 3 Notes”) in an aggregate principal amount of$1.5
million that bear interest at a fixed rate of 8% per annum and
warrants to purchase shares of the Company’scapital stock (the 
“Series 3 Warrants”). The Company initially entered into a
subscription agreement with certainaccredited investors and closed
an initial private placement of the Series 3 Notes in October 2017.
In December 2017, theCompany and holders of a majority in aggregate
principal amount of the Series 3 Notes entered into an amended and
restatedsubscription agreement to amend the terms of the Series 3
Notes and Series 3 Warrants (the “Series 3 Amendment”).The Series 3
Notes require us to repay the principal and accrued and unpaid
interest thereon at December 31, 2018. If theCompany consummates an
equity round of financing resulting in more than $3 million in
gross proceeds before December 31, 2018(the “Series 3 Qualified
Financing”), the outstanding principal and accrued and unpaid
interest on the Series 3Notes shall automatically convert into the
securities issued by us in the Series 3 Qualified Financing equal
to theoutstanding principal and accrued interest on the Series 3
Notes divided by 80% of the price per share of the securitiesissued
by us in the Series 3 Qualified Financing. If a Change of Control
(as defined below) occurs prior to the earlier of aSeries 3
Qualified Financing or December 31, 2018, the Series 3 Notes would,
at the election of the holders of a majority ofthe outstanding
principal amount of the Series 3 Notes, either become payable on
demand as of the closing date of the Changeof Control or become
convertible into shares of Common Stock immediately prior to the
Change of Control at a price per shareequal to the lesser of (i)
the per share value of the Common Stock as determined by our Board
of Directors (the“Board”) as if in connection with the granting of
stock based compensation or in a private sale to a thirdparty in an
arms-length transaction or (ii) at the per share consideration to
be paid in the Change of Control (the date ofany such conversion of
the Series 3 Notes in connection with a Change of Control or Series
3 Qualified Financing, is referredto herein as the “Series 3
Conversion Date”). Change of Control means a merger or
consolidation with anotherentity in which our stockholders do not
own more than 50% of the outstanding voting power of the surviving
entity or thedisposition of all or substantially all of our
assets.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Prior to the Series3 Amendment, if the Company raised more than
$3,000,000 in an equity financing before October 4, 2022, the
outstanding principaland accrued and unpaid interest on the Series
3 Notes would have automatically converted into the securities
issued by the Companyin such financing based on the greater number
of such securities resulting from either (i) the outstanding
principal and accruedinterest on the Series 3 Notes divided by
$2.25 or (ii) the outstanding principal and accrued interest on the
Series 3 Notes multipliedby 1.25, divided by the price paid per
security in such financing.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The Series 3 Notesare unsecured. If we fail to complete a Series 3
Qualified Financing by December 31, 2018, the Series 3 Notes will
be immediatelydue and payable on such date.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p>
<!-- Field: Page; Sequence: 27; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Each Series 3Warrant grants the holder the option to purchase
shares of our capital stock equal to the number of shares of
capital stockof the Company received by the holder upon conversion
of the Series 3 Notes at a per share exercise price equal to (i)
theactual per share price of the securities issued in the Series 3
Qualified Financing if the Series 3 Notes convert inconnection with
such a qualified financing or (ii) the price at which the Series 3
Noted converted if they converted inconnection with a Change of
Control. The Series 3 Warrants are exercisable commencing on the
Series 3 Conversion Date andexpiring on the five year anniversary
of that date. The exercise price and number of the shares of our
capital stock issuableupon exercising the &nbsp;Series 3 Warrants
will be subject to adjustment in the event of any stock dividends
and splits,reverse stock split, recapitalization, reorganization,
business combination or similar transaction, as described
therein.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<u>Series 2 Notes and Warrants</u></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
In August 2017, theCompany entered into a subscription agreement
and issued interest free promissory notes in an aggregate principal
amount of $253,000to certain accredited investors. In November
2017, the Company and each subscriber amended the notes. In March
2018, the Companyand each subscriber entered into a written consent
to amend and restate the promissory notes (as amended, the “Series
2Notes”) and to amend the subscription agreement to replace the
form of warrant agreement annexed to the subscription agreement(the
“Replacement Warrant”) and to provide for the issuance of an
additional warrant (the “Additional Warrant”).In March 2018 the
Company issued and delivered the Series 2 Notes, the Replacement
Warrants and the Additional Warrants to thesubscribers.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The Series 2 Notes,as amended in March 2018, are now convertible
promissory notes that bear interest at a fixed rate of 8% per annum
and requirethe Company to repay the principal and accrued and
unpaid interest thereon on the maturity date of July 31, 2018. If
the Companyraises more than $3,000,000 in an equity or
equity-linked financing before July 31, 2018 (the “Series 2
Qualified Financing”),the outstanding principal and accrued and
unpaid interest (the “Outstanding Balance”) on the Series 2 Notes
shallautomatically convert into the securities issued by us in the
Series 2 Qualified Financing (the “New Round Stock”)based on the
greater number of such securities resulting from either (i) the
Outstanding Balance divided by $1.80 or (ii) theOutstanding Balance
multiplied by 1.25, divided by the price paid per security in the
Series 2 Qualified Financing. If a Changeof Control occurs prior to
the earlier of a Series 2 Qualified Financing or July 31, 2018, the
Series 2 Notes would, at the electionof the holders of a majority
of the outstanding principal of the Series 2 Notes, either become
payable on demand as of the closingdate of such transaction or
become convertible into shares of Common Stock immediately prior to
such transaction at a price pershare equal to the lesser of (i) the
per share value of the Common Stock as determined by the Board as
if in connectionwith the granting of stock based compensation or in
a private sale to a third party in an arms-length transaction or
(ii) at theper share consideration to be paid in such transaction
(the date of any such conversion of the Series 2 Notes in
connection witha Change of Control or Series 2 Qualified Financing,
is referred to herein as the “Series 2 Conversion Date”). TheSeries
2 Notes are unsecured.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Each Replacement Warrantgrants the holder the option to purchase up
to the number of shares of capital stock of the Company equal to
the New Round Stockissued or issuable upon the conversion of the
Series 2 Note&nbsp;held by such holder at a per share exercise
price equal to either(i) the actual per share price of New Round
Stock if the Series 2 Note &nbsp;converted in connection with a
Series 2 QualifiedFinancing or (ii) the price at which the Series
2&nbsp;Note&nbsp;converted in connection with a Change of Control.
The ReplacementWarrants are exercisable commencing on the Series 2
Conversion Date and expire on November 21, 2021.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Each Additional Warrantgrants the holder the option to purchase up
to the number of shares of capital stock of the Company equal to
the product obtainedby multiplying (i) the outstanding principal
amount of the Series 2 Note&nbsp;held by such holder and (ii) 0.75;
at a per shareexercise price of $1.80. The Additional Warrants are
exercisable commencing on the Series 2 Conversion Date and expire
on November21, 2021.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The exercise priceand number of the shares issuable upon exercising
the Replacement Warrants and Additional Warrants are subject to
adjustment inthe event of any stock dividends and splits, reverse
stock split, recapitalization, reorganization or similar
transaction, asdescribed therein.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Prior to amendingthe Series 2 Notes in November 2017 and March
2018, the notes were interest free and matured on February 18,
2018. Upon the maturityof the notes, the holder was entitled to
receive a warrant exercisable for up to such number of shares of
Common Stock equal tothe quotient obtained by dividing the
outstanding principal amount by two, at an exercise price of $1.80
per share. In connectionwith the November 2017 amendment, the
maturity date was extended to July 31, 2018 and the number of
shares of Common Stock issuableto the subscribers upon exercise of
the warrants was increased (with each subscriber entitled to
receive a warrant to purchaseup to such number of shares of Common
Stock equal to the amount of such subscriber’s note multiplied by
0.75), at an exerciseprice of $1.80 per share.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p>
<!-- Field: Page; Sequence: 28; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<u>Series 1 Notes and Warrants</u></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
From November 2016to June 2017, the Company issued convertible
promissory notes in an aggregate principal amount of $1.6 million
that bear interestat a fixed rate of 8% per annum and warrants to
purchase shares of the Company’s capital stock. In June 2017 and
November2017, the terms of such notes (as amended, the “Series 1
Notes”) and warrants (as amended, the “Series 1 Warrants”)were
amended.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The Series 1Notes require us to repay the principal and accrued and
unpaid interest thereon at the earlier of July 31, 2018, or
theconsummation of the next equity or equity-linked round of
financing resulting in more than $3 million in gross proceeds (the
“Series 1 Qualified Financing”). If a Series 1 Qualified Financing
occurs before July 31, 2018, the outstandingprincipal and accrued
and unpaid interest on the Series 1 Notes shall automatically
convert into the securities issued by usin the Series 1 Qualified
Financing based on the greater number of such securities resulting
from either (i) the outstandingprincipal and accrued interest on
the Series 1 Notes divided by $1.80 or (ii) the outstanding
principal and accrued intereston the Series 1 Notes multiplied by
1.25, divided by the price paid per security in such financing. If
a Change of Control orinitial public offering occurs prior to the
Series 1 Qualified Financing, the Series 1 Notes would, at the
election of theholders of a majority of the outstanding principal
of the Series 1 Notes, either become payable on demand as of the
closingdate of such transaction or become convertible into shares
of Common Stock immediately prior to such transaction at a priceper
share equal to the lesser of (i) the per share value as determined
by the Board as if in connection withthe granting of stock based
compensation or in a private sale to a third party in an
arms-length transaction or (ii) at theper share consideration to be
paid in such transaction (the date of any such conversion of the
Series 1 Notes in connectionwith a Change of Control, initial
public offering or Series 1 Qualified Financing, is referred to
herein as the “Series1 Conversion Date”).</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The Series 1 Notesare unsecured. If we fail to complete a Series 1
Qualified Financing by July 31, 2018, the Series 1 Notes will be
immediatelydue and payable on such date.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Each Series 1 Warrantgrants the holder the option to purchase up to
the number of shares of capital stock of the Company equal to the
shares of capitalstock received by the holder upon the conversion
of the Series 1 Note at a per share exercise price equal to either
(i) the actualper share price of the securities issued in the
Series 1 Qualified Financing if the Series 1 Note converted in
connection withthe Series 1 Qualified Financing or (ii) the price
at which the Series 1 Note converted in connection with a Change of
Controlor initial public offering. The Series 1 Warrants (other
than the placement agent warrant) are exercisable commencing on the
Series1 Conversion Date and expire on November 21, 2021.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The exercise priceand number of the shares of our capital stock
issuable upon exercising the Series 1 Warrants will be subject to
adjustment inthe event of any stock dividends and splits, reverse
stock split, recapitalization, reorganization, business combination
or similartransaction, as described therein.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
In connection withan engagement letter with the placement agent for
the Series 1 Notes and Series 1 Warrants, the placement agent was
entitled toreceive a warrant to purchase shares of Common Stock in
an amount equal to 8% of the Common Stock purchased by investors in
theSeries 1 Notes and Series 1 Warrants private placement, which
warrants have an exercise price of $2.00 per share. The
placementagent warrant is immediately exercisable and expires five
years from the date of issuance. We also paid the placement agent
acash fee of $113,610 (8% of the gross proceeds received from the
Series 1 Note and Series 1 Warrant investors) and are obligatedto
issue to the placement agent a warrant to purchase shares of Common
Stock in an amount equal to 8% of the Common Stock purchasedby
certain investors in the Series 1 Note and Series 1 Warrant
transaction upon fulfillment of the maximum aggregate
subscriptionamount, which warrant is expected to have an exercise
price of $2.00 per share of our Common Stock.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p>
<!-- Field: Page; Sequence: 29; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<u>Unsecured Loans</u></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
We received cash grossproceeds from an unsecured loan from a
stockholder owning over 5% of the Company’s Common Stock,
represented by a promissorynote for $115,000 in March 2018. The
loan is interest free and requires that we repay the principal in
full on the earlier ofthe closing of an equity round of financing
of the Company resulting in more than $3 million in gross proceeds
or March 20, 2019.We also received cash proceeds from an unsecured
loan for $50,000 in November 2016. We incurred no fees or interest
costsrelated to the unsecured loan and repaid it in full in
February 2017.&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>Funding Requirements and Outlook</i></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
We have no currentsource of revenue to sustain our present
activities, and we do not expect to generate revenue until, and
unless, the FDA or otherregulatory authorities approve our cortical
strip, grid electrode and depth electrode technology under
development and we successfullycommercialize our cortical strip,
grid electrode and depth electrode technology. Until such time, if
ever, as we can generatesubstantial product revenue, we expect to
finance our cash needs through a combination of equity and debt
financings as well ascollaborations, strategic alliances and
licensing arrangements. We do not have any committed external
source of funds. To theextent that we raise additional capital
through the sale of equity or convertible debt securities, the
ownership interest of ourstockholders will be diluted, and the
terms of these securities may include liquidation or other
preferences that adversely affectyour rights as a common
stockholder. Debt financing, if available, may involve agreements
that include covenants limiting or restrictingour ability to take
specific actions, such as incurring additional debt, making capital
expenditures or declaring dividends. Ifwe raise additional funds
through collaborations, strategic alliances or licensing
arrangements with third-party partners, wemay have to relinquish
valuable rights to our technologies, future revenue streams or
grant licenses on terms that may not befavorable to us. If we are
unable to raise additional funds through equity or debt financings
or through collaborations, strategicalliances or licensing
arrangements when needed, we may be required to delay, limit,
reduce or terminate our product development,future
commercialization efforts, or grant rights to develop and market
our cortical strip, grid electrode and depth electrodetechnology
that we would otherwise prefer to develop and market ourselves.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Our independent registeredpublic accounting firm included an
explanatory paragraph in its report on our financial statements as
of and for the years endedDecember 31, 2017 and 2016, noting the
existence of substantial doubt about our ability to continue as a
going concern. This uncertaintyarose from management’s review of
our results of operations and financial condition and its
conclusion that, based on ouroperating plans, we did not have
sufficient existing working capital to fund our operating
expenses.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
As of March 31, 2018,the outstanding principal and accrued and
unpaid interest on the Series 1 Notes, Series 2 Notes and Series 3
Notes was $1,770,839,$254,124 and $1,167,494, respectively. If we
fail to complete the Series 1 Qualified Financing and the Series 2
Qualified Financingby July 31, 2018, the Series 1 Notes and Series
2 Notes will be immediately due and payable on such date and we
will not havesufficient cash to pay the principal and accrued and
unpaid interest thereon. In addition, the Series 3 Notes mature on
December31, 2018 and we may not have sufficient cash to pay the
principal thereon if we fail to complete the Series 3 Qualified
Financingby such date.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
We have agreementswith the Wisconsin Alumni Research Foundation (
“WARF”) and the Mayo Foundation for Medical Education and Research(
“Mayo”) that require us to make certain milestone and royalty
payments.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Under a License Agreementwith WARF, as amended in February 2017
(the “WARF License”), we agreed to pay WARF $55,000 (representing a
licensefee) upon the earliest to occur of the date we cumulatively
raise at least $3 million in financing, which threshold was just
met,the date of a change of control, or our revenue reaching a
specified threshold amount, and to pay $65,000 (representing
reimbursementfor costs incurred by WARF in maintaining the licensed
patents) upon the earliest to occur of the date we cumulatively
raise atleast $5 million in financing, the date of a change of
control, or our revenue reaching a specified threshold amount. The
initial$55,000 payment was due on May 3, 2018 and was paid on April
22, 2018. We have also agreed to pay WARF a royalty equal to a
single-digitpercentage of our product sales pursuant to the WARF
License, with a minimum annual royalty payment of $50,000 for 2019,
$100,000for 2020 and $150,000 for 2021 and each calendar year
thereafter that the WARF License is in effect. If we or any of our
sublicensescontest the validity of any licensed patent, the royalty
rate will be doubled during the pendency of such contest and, if
thecontested patent is found to be valid and would be infringed by
us if not for the WARF License, the royalty rate will be tripledfor
the remaining term of the WARF License.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p>
<!-- Field: Page; Sequence: 30; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Under an Amendedand Restated exclusive license and development
agreement between Mayo and NeuroOne, dated May 25, 2017 (the “Mayo
DevelopmentAgreement”), NeuroOne issued Mayo NeuroOne Shares
pursuant to a subscription agreement (which were converted into
859,976shares of Common Stock in the Acquisition), and NeuroOne
agreed to pay Mayo a cash payment of $91,708.80. Following the
Acquisition,the rights and obligations under the Mayo Development
Agreement transferred to the Company. In November 2017, the Company
andMayo amended the Mayo Development Agreement to extend the
deadline of the cash payment to December 31, 2017, which the
Companypaid in December 2017. Additionally, we have agreed to pay
Mayo a royalty equal to a single-digit percentage of our product
salespursuant to the Mayo Development Agreement.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Our existing cashand cash equivalents will not be sufficient to
fund our operating expenses throughout fiscal 2018. To continue to
fund operations,we will need to secure additional funding. We may
obtain additional financing in the future through the issuance of
our CommonStock, through other equity or debt financings or through
collaborations or partnerships with other companies. We may not be
ableto raise additional capital on terms acceptable to us, or at
all. Further, we may not be able to modify terms of some of our
existingdebt that may come due, and any failure to raise capital or
to amend existing debt that may be due as and when needed could
compromiseour ability to execute on our business plan.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
The development ofour cortical strip, grid electrode and depth
electrode technology is subject to numerous uncertainties, and we
have based theseestimates on assumptions that may prove to be
substantially different than we currently anticipate and could use
our cash resourcessooner than we expect. Additionally, the process
of developing medical devices is costly, and the timing of progress
in pre-clinicaltests and clinical trials is uncertain. Our ability
to successfully transition to profitability will be dependent upon
achievingFDA approval and then a level of product sales adequate to
support our cost structure. We cannot assure you that we will
everbe profitable or generate positive cash flow from operating
activities.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Cash Flows</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
The following is a summary of cash flowsfor each of the periods set
forth below.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><i>&nbsp;</i></b></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td colspan="6" style="font-weight: bold; text-align: center">
For&nbsp;the&nbsp;Three Months Ended</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
March 31,</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"text-align: center; border-bottom: Black 1.5pt solid">
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>2018</b></p>
</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
2017</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="6" style="text-align: center">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Net cash used in operating
activities</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">(591,269</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">(350,919</td>
<td style="width: 1%; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1.5pt">Net cash
provided by financing activities</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
590,000</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
<td style="padding-bottom: 1.5pt">&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">
&nbsp;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">
315,120</td>
<td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; padding-bottom: 4pt">Net decrease in
cash</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
(1,269</td>
<td style="padding-bottom: 4pt; text-align: left">)</td>
<td style="padding-bottom: 4pt">&nbsp;</td>
<td style="border-bottom: Black 4pt double; text-align: left">
$</td>
<td style="border-bottom: Black 4pt double; text-align: right">
(35,799</td>
<td style="padding-bottom: 4pt; text-align: left">)</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>Net cash used in operating activities</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Net cash used inoperating activities was $0.6 million for the three
months ended March 31, 2018, which consisted of a net loss of $1.4
millionpartially offset primarily by non-cash interest, stock-based
compensation for non-employee services, note discount
amortization,revaluation of premium debt conversion derivative and
warrant liabilities and short-term notes extinguishment, totaling
$0.5 millionin the aggregate, and an increase in accrued expenses
of $0.2 million.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Net cash used in operatingactivities was $0.4 million for the three
months ended March 31, 2017, which consisted of a net loss of $0.7
million partiallyoffset by non-cash interest, discount
amortization, and warrant issuance costs on the Series 1 Notes of
$0.2 million, an increasein accrued expenses of $0.1 million, and
an increase in prepaid expenses of $53,823.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
</p>
<!-- Field: Page; Sequence: 31; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<i>Net cash provided by financing activities</i></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Net cash providedby financing activities was $0.6 million for the
three months ended March 31, 2018, which consisted of net proceeds
received uponthe issuance of the Series 3 Notes and Warrants of
$0.5 million and proceeds from an unsecured loan in the amount of
$0.1 millionduring the three month period.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Net cashprovided by financing activities was $0.3 million for the
three months ended March 31, 2017, which consisted of $0.4
millionin net proceeds received upon the issuance of the Series 1
Notes and Series 1 Warrants during the quarter partially offset
bythe $50,000 repayment of a short-term unsecured loan.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><u>Critical Accounting Policies</u></b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">
Our financial statements are prepared inaccordance with U.S.
generally accepted accounting principles. These accounting
principles require us to make estimates and judgments that can
affect the reported amountsof assets and liabilities as of the date
of the financial statements as well as the reported amounts of
revenue and expense duringthe periods presented. We believe that
the estimates and judgments upon which we rely are reasonably based
upon information availableto us at the time that we make these
estimates and judgments. To the extent that there are material
differences between theseestimates and actual results, our
financial results will be affected. The accounting policies that
reflect our more significantestimates and judgments and which we
believe are the most critical to aid in fully understanding and
evaluating our reported financialresults are described in Note 3 — 
“Summary of Significant Accounting Policies” to our condensed
consolidatedfinancial statements included in “Part 1, Item 1 –
Financial Statements” in this Report.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">
During the three months ended March 31,2018, there were no material
changes to our critical accounting policies or estimates disclosed
in “Management’s Discussionand Analysis of Financial Condition and
Results of Operations” included in our Annual Report on Form 10-K
for the year endedDecember 31, 2017.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Recent Accounting Pronouncements</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">
Refer to Note 3— “Summary ofSignificant Accounting Policies” to our
condensed financial statements included in “Part 1, Item 1 –
FinancialStatements” in this Report for a discussion of recently
issued accounting pronouncements.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b><u>Off Balance Sheet Arrangements</u></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
None.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Item 3. Quantitative and Qualitative Disclosures About
MarketRisk</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Not applicable forsmaller reporting companies.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Item 4. Controls and Procedures</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
During the three monthsended March 31, 2018, there were no changes
in our internal controls over financial reporting (as defined in
Rule 13a- 15(f) and15d-15(f) under the Exchange Act) that have
materially affected, or are reasonably likely to materially affect,
our internal controlover financial reporting.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<u>Evaluation of Disclosure Controls andProcedures</u></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
Under the supervisionand with the participation of our management,
including our chief executive officer and principal financial
officer, we conductedan evaluation of our disclosure controls and
procedures, as such term is defined under Rule 13a-15(e) and Rule
15d-15(e) promulgatedunder the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), as of&nbsp;March 31, 2018. Based on
thisevaluation, our chief executive officer and principal financial
officer have concluded such controls and procedures to be
ineffectiveas of March 31, 2018&nbsp;to ensure that information
required to be disclosed by the issuer in the reports that it files
or submitsunder the Exchange Act is recorded, processed, summarized
and reported, within the time periods specified in the Commission’
srules and forms and to ensure that information required to be
disclosed by an issuer in the reports that it files or submits
underthe Exchange Act is accumulated and communicated to the issuer’
s management, including its principal executive and
principalfinancial officers, or persons performing similar
functions, as appropriate to allow timely decisions regarding
required disclosure.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">
Asof March 31, 2018, disclosure controls and procedures were not
effective due to previously identified material weaknesses.
Thematerial weaknesses related to our small size and include the
inability to (i) maintain effective controls over accounting
fornon-routine and/or complex debt and equity transactions and (ii)
maintain effective controls over the financial statement closeand
reporting process, accounting for routine transactions and
segregation of duties.&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
We intend to recruitadditional professionals to address these
material weaknesses, as our business conditions warrant. However,
we do not currentlyhave adequate cash resources to invest in these
additional resources. Accordingly, our remediation plans may be
delayed. Althoughwe believe that these corrective steps, when
taken, will enable management to conclude that the internal
controls over our financialreporting are effective when the staff
is in place and trained, we cannot provide assurance that these
steps will be sufficient.We may be required to expend additional
resources to identify, assess and correct any additional weaknesses
in internal control.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 32; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>PART II – OTHERINFORMATION</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Item 1. Legal Proceedings</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
From time to time,we are subject to litigation and claims arising
in the ordinary course of business.&nbsp; In May 2017, NeuroOne
received a letterfrom PMT, the former employer of Mark Christianson
and Wade Fredrickson.&nbsp; PMT claimed that these officers had
breached theirrestrictive covenant obligations with PMT by virtue
of their work for NeuroOne and such officer’s prior work during
employmentwith the prior employer, that these officers had breached
their confidentiality and non-disclosure obligations to PMT and
federaland state law by misappropriating confidential and trade
secret information, and that NeuroOne is responsible for tortious
interferencewith the contracts.&nbsp; The letter demanded that Mr.
Fredrickson (who is no longer with NeuroOne), Mr. Christianson and
NeuroOnecease and desist all competitive activities, that Mr.
Fredrickson step down from his position and that Mr. Christianson
and NeuroOneprovide the former employer access to NeuroOne’s
systems to demonstrate that it is not using trade secrets or
proprietaryinformation nor competing with the former employer.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
On March 29, 2018,we were served with a complaint filed by PMT
adding the Company, NeuroOne and Mr. Christianson to its existing
lawsuit againstMr. Fredrickson.&nbsp; In the lawsuit, PMT claims
that Mr. Fredrickson and Mr. Christianson breached their
non-competition, non-solicitationand non-disclosure obligations,
breached their fiduciary duty obligations, were unjustly enriched,
engaged in unfair competition,engaged in a civil conspiracy,
tortiously interfered with PMT’s contracts and prospective economic
advantage, and breacheda covenant of good faith and fair
dealing.&nbsp; Against Mr. Fredrickson, PMT also alleges that he
intentionally or negligentlyspoliated evidence, made negligent or
fraudulent misrepresentations, misappropriated trade secrets in
violation of Minnesota law,and committed the tort of conversion and
statutory civil theft. Against the Company and NeuroOne, PMT
alleges that the Companyand NeuroOne were unjustly enriched and
engaged in unfair competition.&nbsp; PMT asks the Court to impose a
constructive trustover the shares held by Mr. Fredrickson and Mr.
Christianson and to award compensatory damages, equitable relief,
punitive damages,attorneys’ fees, costs and interest. The Company,
NeuroOne and Mr. Christianson (who has not worked for PMT since
2012)intend to defend themselves vigorously.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
We have no insurancecoverage to protect against any losses we may
experience due to this claim. Furthermore, Mr. Christianson is a
key officer andthe loss of his services would be detrimental to our
operations and prospects.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
</p>
<!-- Field: Page; Sequence: 33; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>&nbsp;</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Item 1A. &nbsp;Risk Factors</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">
In addition to the other information setforth elsewhere in this
Report, you should carefully consider the factors discussed in Part
I, Item 1A “Risk Factors”of the Company’s Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2017. Those
factors, if they wereto occur, could cause our actual results to
differ materially from those expressed in our forward-looking
statements in this Report,and materially adversely affect our
financial condition or future results. Although we are not aware of
any other factors thatwe currently anticipate will cause our
forward-looking statements to differ materially from our future
actual results, or materiallyaffect the Company’s financial
condition or future results, additional risks and uncertainties not
currently known to usor that we currently deem to be immaterial
might materially adversely affect our actual business, financial
condition and/or operatingresults.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
<b>Item 2. Unregistered Sales of EquitySecurities and Use of
Proceeds</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
None.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Item 3. &nbsp;Defaults Upon Senior Securities.</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 45.75pt">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
None.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Item 4. &nbsp;Mine Safety Disclosures</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 45.75pt">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
Not applicable to our Company.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Item 5. &nbsp;Other Information</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
None.</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
<b>Item 6. &nbsp;Exhibits</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">
&nbsp;</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"width: 14%; text-indent: 0; padding: 0; text-align: left; vertical-align: top">
Exhibit 10.1</td>
<td style=
"width: 86%; text-align: justify; padding: 0; text-indent: 0">
<a href=
"http://www.sec.gov/Archives/edgar/data/1500198/000121390018003074/f8k031218ex4-1_neuroone.htm">
Form of Amended and Restated Note issued pursuant to August 2017
Subscription Agreement, as amended (incorporated by reference to
Exhibit 4.1 on the Registrant’s Current Report on Form 8-K filed on
March 16, 2018).</a></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-indent: 0; padding: 0; text-align: left; vertical-align: top">
&nbsp;</td>
<td style="text-align: justify; padding: 0; text-indent: 0">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-indent: 0; padding: 0; text-align: left; vertical-align: top">
Exhibit 10.2</td>
<td style="text-align: justify; padding: 0; text-indent: 0">
<a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390018003074/f8k031218ex4-2_neuroone.htm">
Form of Replacement Warrant issued pursuant to August 2017
Subscription Agreement, as amended (incorporated by reference to
Exhibit 4.2 on the Registrant’s Current Report on Form 8-K filed on
March 16, 2018).</a></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-indent: 0; padding: 0; text-align: left; vertical-align: top">
&nbsp;</td>
<td style="text-align: justify; padding: 0; text-indent: 0">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-indent: 0; padding: 0; text-align: left; vertical-align: top">
Exhibit 10.3</td>
<td style="text-align: justify; padding: 0; text-indent: 0">
<a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390018003074/f8k031218ex4-3_neuroone.htm">
Form of Additional Warrant issued pursuant to August 2017
Subscription Agreement, as amended (incorporated by reference to
Exhibit 4.3 on the Registrant’s Current Report on Form 8-K filed on
March 16, 2018).</a></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-indent: 0; padding: 0; text-align: left; vertical-align: top">
&nbsp;</td>
<td style="text-align: justify; padding: 0; text-indent: 0">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-indent: 0; padding: 0; text-align: left; vertical-align: top">
Exhibit 10.4</td>
<td style="text-align: justify; padding: 0; text-indent: 0">
<a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390018004509/f10k2017ex10-40_neuroone.htm">
Non-Employee Director Compensation Policy (incorporated by
reference to Exhibit 10.40 on the Registrant’s Annual Report on
Form 10-K filed on April 16, 2018).</a></td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-indent: 0; padding: 0; text-align: left; vertical-align: top">
&nbsp;</td>
<td style="text-align: justify; padding: 0; text-indent: 0">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-indent: 0; padding: 0; text-align: left; vertical-align: top">
Exhibit 10.5</td>
<td style="text-align: justify; padding: 0; text-indent: 0">
<a href="http://www.sec.gov/Archives/edgar/data/1500198/000121390018004509/f10k2017ex10-41_neuroone.htm">
Lock-up Agreement, effective as of March 1, 2018 by and between
Wade Fredrickson and the Company (incorporated by reference to
Exhibit 10.41 on the Registrant’s Annual Report on Form 10-K filed
on April 16, 2018).</a></td>
</tr>
<tr style="background-color: White">
<td style="text-align: left; vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="text-align: left; vertical-align: top"><font style=
"font-size: 10pt">Exhibit 31</font></td>
<td style="vertical-align: bottom; text-align: justify"><a href=
"f10q0318ex31_neuroonemedical.htm"><font style=
"font-size: 10pt">Certifications pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.</font></a></td>
</tr>
<tr style="background-color: White">
<td style="text-align: left; vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td style="text-align: left; vertical-align: top"><font style=
"font-size: 10pt">Exhibit 32</font></td>
<td style="vertical-align: bottom; text-align: justify"><a href=
"f10q0318ex32_neuroonemedical.htm"><font style=
"font-size: 10pt">Certifications pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.</font></a></td>
</tr>
<tr style="background-color: White">
<td style="text-align: left; vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td nowrap="nowrap" style="text-align: left; vertical-align: top">
<font style="font-size: 10pt">Exhibit 101.INS</font></td>
<td style="vertical-align: bottom; text-align: justify">
<font style="font-size: 10pt">XBRL Instance Document.</font></td>
</tr>
<tr style="background-color: White">
<td nowrap="nowrap" style="text-align: left; vertical-align: top">
&nbsp;</td>
<td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td nowrap="nowrap" style="text-align: left; vertical-align: top">
<font style="font-size: 10pt">Exhibit 101.SCH</font></td>
<td style="vertical-align: bottom; text-align: justify">
<font style="font-size: 10pt">XBRL Taxonomy Extension Schema
Document.</font></td>
</tr>
<tr style="background-color: White">
<td nowrap="nowrap" style="text-align: left; vertical-align: top">
&nbsp;</td>
<td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td nowrap="nowrap" style="text-align: left; vertical-align: top">
<font style="font-size: 10pt">Exhibit 101.CAL</font></td>
<td style="vertical-align: bottom; text-align: justify">
<font style="font-size: 10pt">XBRL Taxonomy Extension Calculation
Linkbase Document.</font></td>
</tr>
<tr style="background-color: White">
<td nowrap="nowrap" style="text-align: left; vertical-align: top">
&nbsp;</td>
<td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td nowrap="nowrap" style="text-align: left; vertical-align: top">
<font style="font-size: 10pt">Exhibit 101.DEF</font></td>
<td style="vertical-align: bottom; text-align: justify">
<font style="font-size: 10pt">XBRL Taxonomy Extension Definition
Linkbase Document.</font></td>
</tr>
<tr style="background-color: White">
<td nowrap="nowrap" style="text-align: left; vertical-align: top">
&nbsp;</td>
<td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td nowrap="nowrap" style="text-align: left; vertical-align: top">
<font style="font-size: 10pt">Exhibit 101.LAB</font></td>
<td style="vertical-align: bottom; text-align: justify">
<font style="font-size: 10pt">XBRL Taxonomy Extension Label
Linkbase Document.</font></td>
</tr>
<tr style="background-color: White">
<td nowrap="nowrap" style="text-align: left; vertical-align: top">
&nbsp;</td>
<td style="vertical-align: bottom; text-align: justify">&nbsp;</td>
</tr>
<tr style="background-color: rgb(204,238,255)">
<td nowrap="nowrap" style="text-align: left; vertical-align: top">
<font style="font-size: 10pt">Exhibit 101.PRE</font></td>
<td style="vertical-align: bottom; text-align: justify">
<font style="font-size: 10pt">XBRL Taxonomy Extension Presentation
Linkbase Document.</font></td>
</tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>
<!-- Field: Page; Sequence: 34; Value: 1 -->
<div style=
"margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font-size: 10pt">
<tr style="vertical-align: top; text-align: left">
<td style="width: 33%">&nbsp;</td>
<td style="width: 34%; text-align: center">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32
<!-- Field: /Sequence --></td>
<td style="width: 33%; text-align: right">&nbsp;</td>
</tr>
</table>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
NeuroOne MedicalTechnologies Corporation</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
Form 10-Q</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>SIGNATURES</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
Pursuant to the requirements of the SecuritiesExchange Act of 1934,
the registrant has duly caused this Report to be signed on its
behalf by the undersigned thereunto dulyauthorized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
Dated: May 15, 2018</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
NeuroOne Medical Technologies Corporation&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
&nbsp;</p>
<table cellspacing="0" cellpadding="0" style=
"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 4%"><font style="font-size: 10pt">By:</font></td>
<td style="width: 36%; border-bottom: black 1.5pt solid">
<font style="font-size: 10pt">/s/ Dave Rosa</font></td>
<td style="width: 60%">&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td><font style="font-size: 10pt">Dave Rosa</font></td>
<td>&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td><font style="font-size: 10pt">Chief Executive
Officer</font></td>
<td>&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td><font style="font-size: 10pt">(Principal Executive
Officer)</font></td>
<td>&nbsp;</td>
</tr>
<tr style="vertical-align: top">
<td>&nbsp;</td>
<td><font style="font-size: 10pt">(Principal Financial
Officer)</font></td>
<td>&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
<b>&nbsp;</b></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
33</p>
<!-- Field: Rule-Page -->
<div align="left" style="margin-top: 0; margin-bottom: 0">
<div style=
"font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">
&nbsp;</div>
</div>
<!-- Field: /Rule-Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<b>&nbsp;</b></p>
</body>
</html>

